<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Inherit Metab Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Inherit. Metab. Dis</journal-id>
<journal-title-group>
<journal-title>Journal of Inherited Metabolic Disease</journal-title>
</journal-title-group>
<issn pub-type="ppub">0141-8955</issn>
<issn pub-type="epub">1573-2665</issn>
<publisher>
<publisher-name>Springer Netherlands</publisher-name>
<publisher-loc>Dordrecht</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29948482</article-id>
<article-id pub-id-type="pmc">6326993</article-id>
<article-id pub-id-type="publisher-id">205</article-id>
<article-id pub-id-type="doi">10.1007/s10545-018-0205-0</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Postsynaptic movement disorders: clinical phenotypes, genotypes, and disease mechanisms</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Abela</surname>
<given-names>Lucia</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kurian</surname>
<given-names>Manju A.</given-names>
</name>
<address>
<phone>+44 (0)20 7905 2824</phone>
<email>manju.kurian@ucl.ac.uk</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution>Molecular Neurosciences, Developmental Neuroscience, </institution><institution>UCL Institute of Child Health, </institution></institution-wrap>London, UK </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution>Developmental Neurosciences Programme, </institution><institution>UCL GOS - Institute of Child Health, </institution></institution-wrap>30 Guilford Street, London, WC1N 1EH UK </aff>
</contrib-group>
<author-notes>
<fn fn-type="com">
<p>Responsible Editor: Georg Hoffmann</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>13</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2018</year>
</pub-date>
<volume>41</volume>
<issue>6</issue>
<fpage>1077</fpage>
<lpage>1091</lpage>
<history>
<date date-type="received">
<day>28</day>
<month>2</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>13</day>
<month>5</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>5</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2018</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Movement disorders comprise a group of heterogeneous diseases with often complex clinical phenotypes. Overlapping symptoms and a lack of diagnostic biomarkers may hamper making a definitive diagnosis. Next-generation sequencing techniques have substantially contributed to unraveling genetic etiologies underlying movement disorders and thereby improved diagnoses. Defects in dopaminergic signaling in postsynaptic striatal medium spiny neurons are emerging as a pathogenic mechanism in a number of newly identified hyperkinetic movement disorders. Several of the causative genes encode components of the cAMP pathway, a critical postsynaptic signaling pathway in medium spiny neurons. Here, we review the clinical presentation, genetic findings, and disease mechanisms that characterize these genetic postsynaptic movement disorders.</p>
</abstract>
<funding-group>
<award-group>
<funding-source>
<institution>University College London (UCL)</institution>
</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© SSIEM 2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p id="Par2">Movement disorders comprise a heterogeneous group of diseases characterized by either an excess of abnormal movements (hyperkinesia) or a lack of normal movements (hypokinesia) (Stoessl and Mckeown <xref ref-type="bibr" rid="CR116">2016</xref>). The phenotypes can be complex and overlapping, particularly in children, and can even change or evolve over time (Stoessl and Mckeown <xref ref-type="bibr" rid="CR116">2016</xref>; Kurian and Dale <xref ref-type="bibr" rid="CR66">2016</xref>). For many movement disorders, there are no biomarkers available to aid diagnosis. However, recent genetic advances have greatly contributed to improved diagnosis for patients with movement disorders (Olgiati et al. <xref ref-type="bibr" rid="CR93">2016</xref>; Reale et al. <xref ref-type="bibr" rid="CR102">2018</xref>). Over the past few years, a number of new genetic movement disorders have been identified, some of which are caused by alterations in genes involved in postsynaptic pathways. Indeed, defects in postsynaptic dopaminergic signaling in striatal medium spiny neurons are emerging as key drivers in the development of a number of genetic hyperkinetic movement disorders. In this review, we discuss the clinical presentation, management, genetic findings, and current understanding of contributory pathogenic mechanisms of such genetic movement disorders associated with striatal postsynaptic dysfunction.</p>
<sec id="Sec2">
<title>Synaptic physiology</title>
<p id="Par3">Synapses are complex neuronal structures that are organized in several cellular compartments including the axon terminal membrane of the presynaptic neuron, the synaptic cleft, and the postsynaptic density (PSD) of the adjacent neuron. Synapses contain functionally and structurally distinct molecular machineries for synaptic connectivity and neurotransmission, the very essential processes that underlie brain function. Depending on the brain area, neurons interconnect with thousands of others and form dense, overlapping, and interdigitated networks that define the brain’s connectivity. Synaptic signaling is characterized not only by the anatomical organization of neurons but also by distinct neurotransmitter systems, which include amino acids (e.g., inhibitory GABA, excitatory glutamate), monoamines (e.g., dopamine, serotonin), peptides, purines, trace amines, and acetylcholine (Hyman <xref ref-type="bibr" rid="CR52">2005</xref>). In chemical synapses, arrival of electrical signal results in membrane depolarization and influx of calcium into the presynaptic terminal, which ultimately results in release of neurotransmitters into the synaptic cleft (Südhof <xref ref-type="bibr" rid="CR119">2013</xref>). Neurotransmission is a spatially and temporally precisely regulated process that involves the concerted interaction of specific proteins at the pre- and postsynaptic sites. Neurotransmitters are stored and transported in defined structures, known as synaptic vesicles (SVs). SVs are organized in distinct pools at the presynaptic terminal including a reserve pool, a recycling pool, and a primed or readily releasable pool (Rizzoli and Betz <xref ref-type="bibr" rid="CR104">2005</xref>). Release of the SV content involves a dedicated molecular machinery and includes several steps: SV priming, docking, and calcium-mediated fusion to the cell membrane (Rizo and Xu <xref ref-type="bibr" rid="CR103">2015</xref>). To ensure repetitive and sustained transmission, SVs have to be rapidly recycled. SV recycling is a complex process and involves several endocytic pathways for the retrieval of SV components from the plasma membrane and regeneration of functional SV (Kononenko and Haucke <xref ref-type="bibr" rid="CR64">2015</xref>; Soykan et al. <xref ref-type="bibr" rid="CR115">2016</xref>). Upon release, neurotransmitters diffuse across the synaptic cleft and bind to their respective receptors on the postsynaptic membrane which activate downstream signaling cascades. The receptors are attached to the postsynaptic density (PSD), which is a multi-protein complex organized into distinct layers of anchoring membrane molecules, scaffolding molecules, signaling molecules, and cytoskeleton molecules. The PSD is a specific feature of glutamatergic synapses. However, PSD-95, a key component of the PSD, has been also identified in glutamatergic synapses of midbrain dopaminergic neurons (Jang et al. <xref ref-type="bibr" rid="CR55">2015</xref>) and in medium spiny neurons of the human neostriatum (Morigaki and Goto <xref ref-type="bibr" rid="CR85">2015</xref>). The PSD is defined to receive and convert the chemical neurotransmitter signal into electrical and biochemical responses in the postsynaptic neuron (Sheng and Kim <xref ref-type="bibr" rid="CR113">2011</xref>). In general, the pre- and postsynaptic compartments are highly dynamic and modify their function or structure in response to specific synaptic activity.</p>
</sec>
<sec id="Sec3">
<title>Synaptic pathology</title>
<p id="Par4">Given the complex molecular organization of synapses, alterations of its composition, structure, or function can have a severe impact on neuronal function leading to neurological disorders (Waites and Garner <xref ref-type="bibr" rid="CR127">2011</xref>). Overall, synaptic dysfunction may occur at a number of different sites including the following: (1) the neuronal soma and axonal compartment affecting synaptic gene expression, SV synthesis, and trafficking; (2) the presynaptic compartment affecting SV exocytosis, endocytosis and recycling, maintenance of SV pools and proteostasis, and synaptic metabolic homeostasis involving mitochondrial function; (3) the intersynaptic compartment affecting neurotransmission and neurotransmitter recycling; and (4) the postsynaptic compartment affecting function of channels, receptors, and associated downstream signaling cascades. The association of human brain disorders with aberrant synaptic function and structure has led to the new concept of “human synaptopathy” (Lepeta et al. <xref ref-type="bibr" rid="CR69">2016</xref>). In recent years, synaptic dysfunction has been linked to a variety of neuropathological conditions including epilepsy (Hamdan et al. <xref ref-type="bibr" rid="CR48">2009</xref>; Caleo <xref ref-type="bibr" rid="CR14">2009</xref>; Casillas-Espinosa et al. <xref ref-type="bibr" rid="CR20">2012</xref>), movement disorders (Quartarone and Pisani <xref ref-type="bibr" rid="CR99">2011</xref>; Calo et al. <xref ref-type="bibr" rid="CR15">2016</xref>; Schirinzi et al. <xref ref-type="bibr" rid="CR109">2016</xref>; Calabresi et al. <xref ref-type="bibr" rid="CR13">2016</xref>; Matikainen-Ankney et al. <xref ref-type="bibr" rid="CR76">2016</xref>; Lepeta et al. <xref ref-type="bibr" rid="CR69">2016</xref>), intellectual disability (Mircsof et al. <xref ref-type="bibr" rid="CR84">2015</xref>; Crocker-Buque et al. <xref ref-type="bibr" rid="CR29">2016</xref>; Zapata et al. <xref ref-type="bibr" rid="CR131">2017</xref>; Ung et al. <xref ref-type="bibr" rid="CR124">2017</xref>), autism spectrum disorders (Giovedí et al. <xref ref-type="bibr" rid="CR46">2014</xref>; De Rubeis et al. <xref ref-type="bibr" rid="CR32">2014</xref>), psychiatric disorders (Kang et al. <xref ref-type="bibr" rid="CR61">2012</xref>; Fromer et al. <xref ref-type="bibr" rid="CR43">2014</xref>), and neurodegenerative disorders (Musardo and Marcello <xref ref-type="bibr" rid="CR86">2017</xref>). Recent advances in next-generation sequencing technologies and subsequent functional validation of identified genetic variants in patients with distinct neurological disorders have further contributed to understanding the genetic mechanisms underlying these human synaptopathies (Baker et al. <xref ref-type="bibr" rid="CR5">2015</xref>; Lipstein et al. <xref ref-type="bibr" rid="CR71">2017</xref>; Myers et al. <xref ref-type="bibr" rid="CR87">2017</xref>; Guarnieri et al. <xref ref-type="bibr" rid="CR47">2017</xref>; Sadybekov et al. <xref ref-type="bibr" rid="CR105">2017</xref>).</p>
</sec>
<sec id="Sec4">
<title>Postsynaptic dysfunction in brain diseases</title>
<p id="Par5">Recent isolation and proteomic profiling of the PSD of the human neocortex have revealed 1461 proteins (Bayés et al. <xref ref-type="bibr" rid="CR7">2011</xref>). Mutations in over 100 of these proteins cause brain diseases enriched in cognitive, affective, and motor phenotypes (Bayés et al. <xref ref-type="bibr" rid="CR7">2011</xref>). Over time, mutations have been identified in genes encoding postsynaptic receptors, ion channels, and components of associated signaling cascades, and the phenotypic spectrum is ever-expanding. Distinct populations of neurons often show a specific vulnerability to genetic alterations, depending on the genes, proteins, and neurotransmitters they express, and the neural circuits they are connected to. For example, GABAergic neurons are thought to play a key role in a number of genetic epilepsies. Mutations in GABA<sub>A</sub> receptor subunits <italic>GABRA</italic><sub><italic>1</italic></sub>, <italic>GABRB</italic><sub><italic>3</italic></sub>, and <italic>GABRG</italic><sub><italic>2</italic></sub> have been identified in a broad spectrum of different epilepsy syndromes including Dravet syndrome, generalized seizures, epileptic encephalopathies, and febrile seizures (Johannesen et al. <xref ref-type="bibr" rid="CR59">2016</xref>; Shen et al. <xref ref-type="bibr" rid="CR112">2017</xref>; Niturad et al. <xref ref-type="bibr" rid="CR91">2017</xref>). Moreover, mutations in the <italic>GRIN2A</italic> gene encoding the NMDA glutamate receptor α2 subunit are emerging as a key genetic factor in the epilepsy-aphasia spectrum disorders (Kingwell <xref ref-type="bibr" rid="CR63">2013</xref>; Yang et al. <xref ref-type="bibr" rid="CR129">2017</xref>). Dysfunction of excitatory hippocampal neurons has been related to intellectual disability caused by mutations in genes encoding proteins of the PSD complex or interacting components (Zapata et al. <xref ref-type="bibr" rid="CR131">2017</xref>; Ung et al. <xref ref-type="bibr" rid="CR124">2017</xref>). Dysfunction of striatal medium spiny neurons (MSNs) due to alterations in genes encoding key postsynaptic proteins is associated with the pathogenesis of dystonia, dyskinesia, chorea, and parkinsonism.</p>
</sec>
<sec id="Sec5">
<title>Key features of the dopaminergic postsynaptic medium spiny neuron</title>
<p id="Par6">MSNs account for approximately 95% of all neurons in the striatum which represents the main input station of the basal ganglia, a group of distinct subcortical nuclei involved in motor control and behavior (Fisone et al. <xref ref-type="bibr" rid="CR42">2007</xref>). MSNs receive excitatory glutamatergic input from the cortex and the thalamus and modulatory dopaminergic input from the midbrain, in particular from the substantia nigra pars compacta, which innervates the dorsal-lateral striatum, and from the ventral tegmental area, which innervates the medial portion of the dorsal striatum and the ventral striatum (Fisone et al. <xref ref-type="bibr" rid="CR42">2007</xref>). Striatal MSNs give rise to inhibitory GABAergic projections to the globus pallidus (striatopallidal pathway) and the substantia nigra pars reticulata (striatonigral pathway).</p>
<sec id="Sec6">
<title>Dopaminergic signaling in striatal medium spiny neurons</title>
<p id="Par7">According to their output projections, neurotransmitters, and receptors, MSNs can be classified into two groups. D1-type dopamine receptor (DRD1)-expressing MSNs use enkephalin as a co-transmitter and project direct inhibitory monosynaptic fibers to the globus pallidus internal segment (GPi) and subthalamic nucleus (STN) (Chuhma et al. <xref ref-type="bibr" rid="CR25">2011</xref>). D2-type dopamine receptor (DRD2)-expressing MSNs use substance P as a co-transmitter and project indirect excitatory polysynaptic fibers to the same nuclei via the globus pallidus external segment (GPe) and STN (Chuhma et al. <xref ref-type="bibr" rid="CR25">2011</xref>) (Fig. <xref ref-type="fig" rid="Fig1">1</xref>(a)). It is generally believed that direct and indirect MSNs in the dorsal striatum exert opposite effects on the control of movement. Activation of DRD1 stimulates direct striatopallidal pathway MSNs and results in disinhibition of thalamocortical neurons, thus facilitating movement. Activation of DRD2, however, inhibits indirect striatonigral pathway MSNs and leads to inhibition of thalamocortical neurons and suppression of movement (DeLong et al. <xref ref-type="bibr" rid="CR33">2007</xref>). In clinical practice, hyper- and hypokinetic features often coexist, for example, in patients with parkinsonism-dystonia; the reasons for this are not entirely clear, but may be related to developmental age, indicating a complex disruption of basal ganglia motor circuitry.<fig id="Fig1"><label>Fig. 1</label><caption><p>Basal ganglia motor circuits in normal physiology and hyperkinetic movement disorders. (a) Basal ganglia circuits in normal condition showing direct and indirect-pathway projections from dopaminergic neurons of the substantia nigra pars compacta to the subthalamic nucleus, the globus pallidus internal segment, and the substantia nigra pars reticulata. (b) Overactivation of the direct pathway in dystonia, and (c) hypofunction of the indirect pathway in chorea ultimately lead to disinhibition of thalamocortical neurons and hyperkinesia. SNc, substantia nigra pars compacta; Gpe, globus pallidus external segment; STN, subthalamic nucleus; Gpi, globus pallidus internal segment; SNr, substantia nigra pars reticulata; PPN, pedunculopontine nucleus (brainstem)</p></caption><graphic id="MO1" xlink:href="10545_2018_205_Fig1_HTML"></graphic></fig></p>
</sec>
<sec id="Sec7">
<title>cAMP signaling pathway in striatal medium spiny neurons</title>
<p id="Par8">Signaling through DRD1 and DRD2 in postsynaptic MSNs is mainly mediated by the G-protein-coupled receptor (GPCR) cyclic adenosine monophosphate (cAMP) cascade. GPCRs are involved in neurotransmitter action and highly expressed throughout the brain (Gerber et al. <xref ref-type="bibr" rid="CR45">2016</xref>). They share a seven-transmembrane-spanning α-helical segment coupled to a heterotrimeric guanine nucleotide-binding protein (G-protein). G-proteins are composed of three subunits, α, β, and γ, and classified into four distinct families depending on their Gα subunit: stimulatory G-proteins (Gα<sub>s</sub>, Gα<sub>olf</sub>), inhibitory G-proteins (Gα<sub>i,</sub> Gα<sub>o,</sub> Gα<sub>t,</sub> Gα<sub>z</sub>), Gα<sub>q</sub> proteins, and Gα<sub>12/13</sub> proteins (Simon et al. <xref ref-type="bibr" rid="CR114">1991</xref>; Oldham and Hamm <xref ref-type="bibr" rid="CR92">2008</xref>). Binding of the respective neurotransmitters to GPCRs results in catalytic conversion of Gα-bound GDP to GTP and reduces the affinity of the Gα subunit to the Gβγ subunit complex, which subsequently dissociates. The Gα subunit then activates downstream signaling effectors. In striatal MSNs, Gα proteins target the enzyme adenylyl cyclase 5 (AC5), which is involved in generation of the second messenger cAMP. Activation of DRD1 stimulates Gα<sub>olf</sub>-mediated AC5 enzyme activity and increases cAMP levels, whereas activation of DRD2 leads to Gα<sub>i</sub>-mediated inhibition of AC5 activity and decreases cAMP levels (Stoof and Kebabian <xref ref-type="bibr" rid="CR117">1981</xref>; Zhuang et al. <xref ref-type="bibr" rid="CR133">2000</xref>; Hervé et al. <xref ref-type="bibr" rid="CR50">2001</xref>; Lee et al. <xref ref-type="bibr" rid="CR68">2002</xref>) (Fig. <xref ref-type="fig" rid="Fig2">2</xref>). Intracellular levels of cAMP are linked to the activity of protein kinase A (PKA), which phosphorylates downstream effector proteins including ion channels, neurotransmitter receptors, and transcription factors (Fisone et al. <xref ref-type="bibr" rid="CR42">2007</xref>). In striatal MSNs, an increase in cAMP and PKA leads to phosphorylation of the dopamine and cAMP-regulated phosphoprotein of 32 kDa (DARP-32) and the transcription factor cAMP-responsive element-binding protein (CREB). DARP-32 is phosphorylated at the Thr-32 residue and as such acts as an inhibitor of protein phosphatase-1 (PP-1) (Fisone et al. <xref ref-type="bibr" rid="CR42">2007</xref>). This in turn reduces dephosphorylation of downstream target effectors including voltage-dependent calcium channels, NMDA, AMPA, and GABA<sub>A</sub> receptors, and thus has a broad impact on neuronal function (Nairn et al. <xref ref-type="bibr" rid="CR88">2004</xref>). The enzyme phosphodiesterase 10A (PDE10A), a dual cAMP-cGMP phosphodiesterase, constitutes another modulator of cellular cAMP and cGMP levels and is highly abundant in striatal MSNs.<fig id="Fig2"><label>Fig. 2</label><caption><p>Schematic overview on a striatal medium spiny neuron synapse. Dopaminergic signaling in striatal medium spiny neurons is mediated by the cAMP signaling pathway. Activation of D1-type dopamine receptors leads to activation of adenylyl cyclase 5 and subsequent increase in cAMP levels, while activation of D2-type dopamine receptors results in inhibition of adenylyl cyclase 5 and reduced levels of cAMP. cAMP in turn modulates activity of the protein kinase A, which phosphorylates further downstream effectors including DARP-32 and CREB. Arrows indicate mutations in genes involved in postsynaptic dopaminergic signaling in striatal medium spiny neurons</p></caption><graphic id="MO2" xlink:href="10545_2018_205_Fig2_HTML"></graphic></fig></p>
</sec>
<sec id="Sec8">
<title>Dysfunction of medium spiny neurons in movement disorders</title>
<p id="Par9">It has become increasingly evident that disruption of the cAMP signaling pathway contributes to postsynaptic dysfunction that is associated with movement disorders such as dystonia, chorea, and parkinsonism (Table <xref ref-type="table" rid="Tab1">1</xref>). It is hypothesized that altered dopaminergic signaling in striatal MSNs plays a key role in the pathogenesis of movement disorders. Dystonia is postulated to result from overactivity of direct pathway MSNs leading to reduced GPi activity (Fig. <xref ref-type="fig" rid="Fig1">1</xref>(b)). Chorea and ballism may be associated with hypofunction of indirect-pathway MSNs resulting in reduced pallidal output (Fig. <xref ref-type="fig" rid="Fig1">1</xref>(c)). Both mechanisms ultimately lead to inadequate GABAergic inhibition of thalamocortical projections and a hyperkinetic movement disorder. Parkinson’s disease, in contrast, is characterized by dopamine depletion in the substantia nigra leading to increased activity of striatal indirect-pathway neurons. This in turn results in enhanced inhibitory output from GPi and SNr and leads to decreased activity in thalamocortical neurons and a hypokinetic movement disorder (DeLong et al. <xref ref-type="bibr" rid="CR33">2007</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Overview of molecular, genetic, and clinical features of postsynaptic movement disorders related to defects in the cAMP pathway in striatal medium spiny neurons</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Protein</th><th>Postulated effect of mutation on protein function</th><th>Inheritance</th><th>Typical age of onset</th><th>Typical clinical features</th><th>Distinguishing clinical features</th><th>Drugs reported to have some efficacy</th></tr></thead><tbody><tr><td>
<italic>ADCY5</italic>
</td><td>Adenylate cyclase 5</td><td>Gain of function</td><td>AD (familial, de novo, and somatic mosaicism)</td><td>Infancy to childhood</td><td>Generalized chorea, perioral dyskinesia, dystonia and myoclonus, lower limb spasticity, static or mildly progressive</td><td>Fluctuation in severity and frequency of MD, sleep-related episodes of hyperkinesia</td><td>Clonazepam, clobazam, acetazolamide, DBS</td></tr><tr><td>
<italic>PDE10A</italic>
</td><td>Phosphodiesterase 10A</td><td>Loss of function</td><td>AD (de novo)<break></break>AR (biallelic, inheriting one disease allele from each parent)</td><td>Infancy to childhood</td><td>Generalized chorea, orolingual dyskinesia, static or mildly progressive</td><td>Abnormal MRI in heterozygous patients with bilateral T2-hyperintense striatal lesions</td><td>na</td></tr><tr><td>
<italic>GNAO1</italic>
</td><td>Gαo subunit of GPCR</td><td>Loss of function (EE phenotype)<break></break>Gain of function (MD phenotype)</td><td>AD (de novo, somatic, and gonadal somaticism)</td><td>Infancy to childhood</td><td>Spectrum includes EE phenotype: neonatal-/infantile-onset seizures, infantile spasms, dyskinesia<break></break>MD phenotype: Generalized chorea, facial and orolingual dyskinesia, dystonia, progressive</td><td>Severe exacerbations of chorea/ballism with autonomic dysfunction, complex motor stereotypies</td><td>Tetrabenazine and neuroleptics, topiramate, DBS especially for hyperkinetic exacerbations</td></tr><tr><td>
<italic>GNAL1</italic>
</td><td>Gα<sub>olf</sub> subunit of GPCR</td><td>Loss of function</td><td>AD (familial, de novo)<break></break>AR</td><td>Infancy (AR)<break></break>Adulthood (AD)</td><td>Generalized chorea, hypertonia<break></break>Progressive dystonia</td><td>na</td><td>na</td></tr><tr><td>
<italic>GPR88</italic>
</td><td>G-protein coupled receptor 88</td><td>Loss of function</td><td>AR</td><td>Childhood</td><td>Generalized chorea</td><td>na</td><td>na</td></tr></tbody></table><table-wrap-foot><p><italic>AD</italic>, autosomal dominant; <italic>AR</italic>, autosomal recessive; <italic>DBS</italic>, deep brain stimulation; <italic>EE</italic>, epileptic encephalopathy; <italic>MD</italic>, movement disorder; <italic>na</italic>, not available</p></table-wrap-foot></table-wrap></p>
</sec>
</sec>
</sec>
<sec id="Sec9">
<title>Postsynaptic movement disorders</title>
<sec id="Sec10">
<title>Adenylate cyclase 5-related movement disorders</title>
<sec id="Sec11">
<title>Clinical presentation</title>
<p id="Par10">Adenylate cyclase 5 (<italic>ADCY5</italic>)-related disorders comprise a large phenotypic spectrum and include clinical presentations that mimic dyskinetic cerebral palsy, benign hereditary chorea, mitochondrial disorders, paroxysmal dyskinesia, myoclonus-dystonia, and recently alternating hemiplegia of childhood (Chen et al. <xref ref-type="bibr" rid="CR23">2014</xref>, <xref ref-type="bibr" rid="CR24">2015</xref>; Carapito et al. <xref ref-type="bibr" rid="CR16">2015</xref>; Mencacci et al. <xref ref-type="bibr" rid="CR80">2015</xref>; Chang et al. <xref ref-type="bibr" rid="CR21">2016</xref>; Westenberger et al. <xref ref-type="bibr" rid="CR128">2017</xref>; Douglas et al. <xref ref-type="bibr" rid="CR36">2017</xref>). Disease onset occurs typically in infancy or early childhood, and rarely in early adolescence (Fernandez et al. <xref ref-type="bibr" rid="CR41">2001</xref>). The movement disorder is hyperkinetic, mainly characterized by generalized chorea involving the limbs, face, and/or neck. The characteristic perioral and periorbital twitches, formerly described as facial myokymia, were not confirmed by EMG studies, but rather represent a mixture of myoclonic, choreic movements (Tunc et al. <xref ref-type="bibr" rid="CR123">2017</xref>) manifesting as orolingual dyskinesia. Limb dystonia can be a major disease feature. Additional movement abnormalities including myoclonus and lower limbs spasticity with pyramidal signs are frequently reported. Eye movement abnormalities such as saccade initiation failure and upward gaze palsy have been described in a number of patients (Chang et al. <xref ref-type="bibr" rid="CR21">2016</xref>). Abnormal movements may show marked fluctuation in severity and frequency and can be continuous or paroxysmal (Fernandez et al. <xref ref-type="bibr" rid="CR41">2001</xref>; Chen et al. <xref ref-type="bibr" rid="CR23">2014</xref>; Mencacci et al. <xref ref-type="bibr" rid="CR80">2015</xref>). The disease course is usually either static or mildly progressive over time. Many patients suffer severe and painful episodic exacerbations of the movement disorder that can last minutes to hours and may be triggered by emotional stressors, intercurrent infections, or sudden action. Sleep-related worsening of the movement disorder, in particular during drowsiness and awakening, constitutes a specific characteristic feature of <italic>ADCY5</italic>-related disorders. Axial hypotonia, often preceding the movement disorder, is a common finding and rarely associated with weakness (Chen et al. <xref ref-type="bibr" rid="CR24">2015</xref>). Cognition is usually preserved in patients or only mildly impaired. However, severely affected patients may manifest delayed motor and/or language milestones (Chen et al. <xref ref-type="bibr" rid="CR23">2014</xref>). Brain MR imaging is typically normal in <italic>ADCY5</italic>-related disorders (Chen et al. <xref ref-type="bibr" rid="CR24">2015</xref>).</p>
</sec>
<sec id="Sec12">
<title>Genetics</title>
<p id="Par11">Mutations in the <italic>ADCY5</italic> gene were originally identified in a single five-generation German kindred with an autosomal dominant pattern of inheritance, formerly described as familial dyskinesia and facial myokymia (Fernandez et al. <xref ref-type="bibr" rid="CR41">2001</xref>). To date, over 80 patients from 50 affected families have been genetically confirmed (Fernandez et al. <xref ref-type="bibr" rid="CR41">2001</xref>; Chen et al. <xref ref-type="bibr" rid="CR22">2012</xref>, <xref ref-type="bibr" rid="CR24">2015</xref>; Carapito et al. <xref ref-type="bibr" rid="CR16">2015</xref>; Mencacci et al. <xref ref-type="bibr" rid="CR80">2015</xref>; Chang et al. <xref ref-type="bibr" rid="CR21">2016</xref>; Dy et al. <xref ref-type="bibr" rid="CR37">2016</xref>; Westenberger et al. <xref ref-type="bibr" rid="CR128">2017</xref>; Meijer et al. <xref ref-type="bibr" rid="CR78">2017</xref>; Zech et al. <xref ref-type="bibr" rid="CR132">2017</xref>; Douglas et al. <xref ref-type="bibr" rid="CR36">2017</xref>; Tunc et al. <xref ref-type="bibr" rid="CR123">2017</xref>; Carecchio et al. <xref ref-type="bibr" rid="CR19">2017</xref>). Both autosomal dominantly inherited and de novo mutations have been reported. The p.Arg418Trp variant along with the p.Arg418Gln and the p.Arg418Gly variants constitute recurrent mutations in the majority of patients and indicate a mutational hotspot at the arginine 418 residue. In vitro functional assays have demonstrated a gain of function for the p.Arg418Trp and p.Ala726Thr variants (Chen et al. <xref ref-type="bibr" rid="CR23">2014</xref>). Genotype-phenotype correlations suggest that the missense mutation p.Arg418Trp is associated with a more severe phenotype, while p.Arg418Gly, the p.Arg418Gln, and p.Ala726Thr show a milder phenotype (Chen et al. <xref ref-type="bibr" rid="CR24">2015</xref>; Chang et al. <xref ref-type="bibr" rid="CR21">2016</xref>). Somatic mosaicism, responsible for up to 43% of apparently de novo mutations, results in a less severe phenotype with almost complete resolution of symptoms in adulthood reported in one case (Chen et al. <xref ref-type="bibr" rid="CR24">2015</xref>).</p>
</sec>
<sec id="Sec13">
<title>Treatment</title>
<p id="Par12">In <italic>ADCY5</italic>-related movement disorders, therapeutic trials with anticholinergics (trihexyphenidyl), dopamine antagonists (tetrabenazine), and anticonvulsants have shown limited clinical benefit. The benzodiazepines clonazepam (0.1–0.2 mg/kg) and clobazam (0.2 mg/kg) have been reported to improve sleep-related dyskinesia and myoclonic episodes (Chen et al. <xref ref-type="bibr" rid="CR24">2015</xref>; Chang et al. <xref ref-type="bibr" rid="CR21">2016</xref>). Benzodiazepines exert an indirect inhibitory effect on AC5 activity, which might counterbalance the gain of function associated with the p.Arg418Trp mutation (Dan’ura et al. <xref ref-type="bibr" rid="CR30">1988</xref>; Chang et al. <xref ref-type="bibr" rid="CR21">2016</xref>). Acetazolamide has shown a positive effect on chorea in three patients (Carecchio et al. <xref ref-type="bibr" rid="CR19">2017</xref>). Treatment with bilateral GPi deep brain stimulation (GPi-DBS) elicited a positive clinical response (Dy et al. <xref ref-type="bibr" rid="CR37">2016</xref>; Meijer et al. <xref ref-type="bibr" rid="CR78">2017</xref>). Two case reports showed a significant improvement of dyskinesia and dystonia after DBS (Chang et al. <xref ref-type="bibr" rid="CR21">2016</xref>; Meijer et al. <xref ref-type="bibr" rid="CR78">2017</xref>). However, the long-term efficacy of DBS in this condition is largely unknown.</p>
</sec>
<sec id="Sec14">
<title>Molecular mechanisms</title>
<p id="Par13">The enzyme adenylyl cyclase 5, encoded by the gene <italic>ADCY5</italic>, constitutes the major adenylyl cyclase isoform in the brain and is enriched in the striatum, in particular the nucleus accumbens, where it accounts for 80% of AC activity (Matsuoka et al. <xref ref-type="bibr" rid="CR77">1997</xref>). AC5 is a membrane-bound protein that receives signals from striatal GPCRs including DRD1, DRD2, and A2A adenosine receptor (Lee et al. <xref ref-type="bibr" rid="CR68">2002</xref>). AC5 converts adenosine triphosphate (ATP) into cAMP upon GPCR-activation (Hanoune et al. <xref ref-type="bibr" rid="CR49">1997</xref>). Functional studies into <italic>ADCY5</italic> gain of function mutations in an in vitro HEK293 overexpression cell model demonstrated an increase in intracellular cAMP levels (Chen et al. <xref ref-type="bibr" rid="CR23">2014</xref>). The AC5 knockout mouse model in contrast, mimicking loss of function, exhibits a hypokinetic phenotype with parkinsonian features (Iwamoto et al. <xref ref-type="bibr" rid="CR53">2003</xref>). In <italic>Adcy5</italic><sup><italic>−</italic></sup><italic>/</italic><sup><italic>−</italic></sup> mice, attenuation of DRD2 signaling was associated with abnormal coordination, while attenuated locomotion activity was due to defective DRD1 signaling (Iwamoto et al. <xref ref-type="bibr" rid="CR53">2003</xref>). In striatal MSNs, AC5 constitutes a key enzyme involved in the modulation of dopaminergic signals and is thus tightly associated with motor control.</p>
</sec>
</sec>
<sec id="Sec15">
<title>Phosphodiesterase 10A-related movement disorders</title>
<sec id="Sec16">
<title>Clinical presentation</title>
<p id="Par14">The phenotypic spectrum of <italic>PDE10A</italic>-related disorders is strongly correlated to the mutation dosage. In patients carrying a single heterozygous <italic>PDE10A</italic> variant, disease onset occurs between 5 and 15 years of age. The movement disorder is characterized by chorea that tends to generalize over time. Esposito and colleagues recently described a patient with generalized, non-progressive chorea and diurnal fluctuation that gradually improved during the day and was absent at night (Esposito et al. <xref ref-type="bibr" rid="CR38">2017</xref>). The disease course is usually mildly progressive. Patients with dominant <italic>PDE10A</italic> mutations usually manifest normal cognition and development. Brain MR images show characteristic symmetrical bilateral T2-hyperintense lesions of the striatum (Mencacci et al. <xref ref-type="bibr" rid="CR81">2016</xref>; Esposito et al. <xref ref-type="bibr" rid="CR38">2017</xref>). In contrast, patients harboring recessive <italic>PDE10A</italic> mutations are more severely affected. They usually present with chorea in the first year of life. Facial involvement with orolingual dyskinesia was found in six patients of one kindred and resulted in severe dysarthria and drooling (Diggle et al. <xref ref-type="bibr" rid="CR34">2016</xref>). Reported patients with homozygous mutations had additional neurological features including delayed motor and speech development, cognitive decline, and axial hypotonia (Diggle et al. <xref ref-type="bibr" rid="CR34">2016</xref>). Focal epilepsy has been described in one patient (Diggle et al. <xref ref-type="bibr" rid="CR34">2016</xref>). Brain MRI of patients with recessive disease does not show any structural abnormalities of the basal ganglia, though investigation with a specific PDE10A PET ligand revealed significant loss of striatal PDE10A in one patient (Diggle et al. <xref ref-type="bibr" rid="CR34">2016</xref>).</p>
</sec>
<sec id="Sec17">
<title>Treatment</title>
<p id="Par15">Management of <italic>PDE10A</italic>-related disorders is based on the symptomatic treatment of chorea. In other neurological disorders including Huntington’s disease (HD) and schizophrenia, PDE10A has long been considered a promising target for pharmacological treatment (Menniti et al. <xref ref-type="bibr" rid="CR83">2007</xref>; Raheem et al. <xref ref-type="bibr" rid="CR101">2016</xref>). In these disorders, perturbation of striatal output has been associated with disease pathophysiology (Raheem et al. <xref ref-type="bibr" rid="CR101">2016</xref>; Beaumont et al. <xref ref-type="bibr" rid="CR8">2016</xref>). In HD, dysfunction of indirect MSNs is thought to be responsible for the hyperkinetic movement disorder in the early stage of the disease, which is mainly characterized by chorea (Beaumont et al. <xref ref-type="bibr" rid="CR8">2016</xref>). Reduced levels of PDE10A have been found in HD patients and HD mouse models (Beaumont et al. <xref ref-type="bibr" rid="CR8">2016</xref>). Pharmacologic inhibition of PDE10A in particular enhanced activity and cortical responsiveness of indirect-pathway MSNs and restored defective basal ganglia corticostriatal circuitry, thus mimicking DRD2 agonists (Beaumont et al. <xref ref-type="bibr" rid="CR8">2016</xref>). Hence, PDE10A inhibitors might in the future provide a potential therapy for the hyperkinetic features of both HD disease and <italic>PDE10A</italic>-related disorders.</p>
</sec>
<sec id="Sec18">
<title>Genetics</title>
<p id="Par16">To date, two recessive homozygous <italic>PDE10A</italic> mutations (p.Tyr107Cys and p.Ala116Pro) have been identified in eight individuals from two consanguineous families. Two recurrent de novo dominant heterozygous <italic>PDE10A</italic> missense mutations (p.Phe300Leu and p.Phe334Leu) have been reported in four unrelated individuals and in members of a family with an autosomal dominant mode of inheritance (Diggle et al. <xref ref-type="bibr" rid="CR34">2016</xref>; Mencacci et al. <xref ref-type="bibr" rid="CR81">2016</xref>; Esposito et al. <xref ref-type="bibr" rid="CR38">2017</xref>). Both recessive and dominant mutations result in loss of function and reduced levels of PDE10A in the striatum (Diggle et al. <xref ref-type="bibr" rid="CR34">2016</xref>; Mencacci et al. <xref ref-type="bibr" rid="CR81">2016</xref>). In silico modeling of the p.Phe300Leu and p.Phe334Leu variants demonstrated that the affected amino acids reside within the regulatory GAF-B-binding domain, which stimulates PDE10A activity upon binding of cAMP (Mencacci et al. <xref ref-type="bibr" rid="CR81">2016</xref>). In vitro studies verified severly affected cAMP-binding properties (Mencacci et al. <xref ref-type="bibr" rid="CR81">2016</xref>). As previously described, genotype-phenotype correlations suggest a milder phenotype associated with dominant heterozygous mutations and a more severe phenotype related to homozygous recessive mutations.</p>
</sec>
<sec id="Sec19">
<title>Molecular mechanisms</title>
<p id="Par17"><italic>PDE10A</italic> encodes the enzyme phosphodiesterase 10A, a dual cAMP-cGMP phosphodiesterase, which is highly abundant in MSNs of the striatum (Coskran et al. <xref ref-type="bibr" rid="CR27">2006</xref>). PDE10A catalyzes the hydrolysis of cAMP and cGMP to their corresponding degradation products nucleoside 5′-monophosphate and thus regulates both cAMP and cGMP downstream signaling cascades. PDE10A is involved in the modulation of DRD1- and DRD2-activated GPCR-signaling and in the control of striatal gene expression (Strick et al. <xref ref-type="bibr" rid="CR118">2010</xref>; Diggle et al. <xref ref-type="bibr" rid="CR34">2016</xref>). Pharmacological studies revealed that inhibition of PDE10A preferentially targets indirect-pathway MSNs resulting in suppression of movement and hypokinesia (Threlfell et al. <xref ref-type="bibr" rid="CR121">2009</xref>). Indeed, <italic>Pde10a</italic>-knockout-mice and <italic>Pde10a-</italic>knock-in mice (p.Tyr97Cys variant) show reduced striatal PDE10A levels and manifest hypokinetic movement abnormalities (Schmidt et al. <xref ref-type="bibr" rid="CR110">2008</xref>; Diggle et al. <xref ref-type="bibr" rid="CR34">2016</xref>). In humans, biallelic mutations in the <italic>PDE10A</italic> gene are also associated with reduced striatal levels of PDE10A, but in contrast, a hyperkinetic movement disorder. This observation may reflect species-specific effects and is reminiscent of the situation in HD disease. In both human patients and the corresponding HD mouse models, striatal levels of PDE10A are reduced (Beaumont et al. <xref ref-type="bibr" rid="CR8">2016</xref>). However, HD patients typically manifest an early, hyperkinetic movement phase followed by a hypokinetic phase in the later stage of disease. However, very few HD mouse models accurately recapitulate the early hyperkinetic phase which characterizes the early stage of disease (Diggle et al. <xref ref-type="bibr" rid="CR34">2016</xref>). As is the case for many human movement disorders, the mouse model only partially reflects the disease evident in human patients.</p>
</sec>
</sec>
<sec id="Sec20">
<title>G proteinα<sub>o</sub>-related disorders</title>
<sec id="Sec21">
<title>Clinical presentation</title>
<p id="Par18">The G proteinα<sub>o</sub> (GNAO1)-related phenotypic spectrum includes a spectrum of overlapping neurological phenotypes, including early-onset epileptic encephalopathy (EE), drug-resistant epilepsy with movement disorder (chorea, athetosis, dystonia, stereotypies) and movement disorder (mainly chorea and athetosis) without seizures. Patients with the epileptic encephalopathy phenotype usually manifest neonatal or infantile-onset tonic seizures or infantile spasms and exhibit distinct EEG features including burst suppression or hypsarrhythmia. Affected patients exhibit severe developmental delay and later may develop a dyskinetic movement disorder (Nakamura et al. <xref ref-type="bibr" rid="CR89">2013</xref>; Talvik et al. <xref ref-type="bibr" rid="CR120">2015</xref>; Saitsu et al. <xref ref-type="bibr" rid="CR106">2016</xref>; Marcé-Grau et al. <xref ref-type="bibr" rid="CR73">2016</xref>; Danti et al. <xref ref-type="bibr" rid="CR31">2017</xref>). This condition is currently classified as EEI17 (MIM no. 615473). The movement disorder phenotype is mainly characterized by progressive chorea and dystonia that usually develops in the first few years of life. Dyskinesia, in particular facial and orolingual, dystonia, and complex motor stereotypies have been commonly reported (Saitsu et al. <xref ref-type="bibr" rid="CR106">2016</xref>; Ananth et al. <xref ref-type="bibr" rid="CR3">2016</xref>; Danti et al. <xref ref-type="bibr" rid="CR31">2017</xref>). The onset of movement disorder is often preceded by marked hypotonia and neurodevelopmental delay. With increasing age, many patients develop severe exacerbations and suffer from episodes of refractory chorea and ballismus often accompanied by autonomic dysfunction with tachycardia, hyperthermia, hypertension, and diaphoresis (Ananth et al. <xref ref-type="bibr" rid="CR3">2016</xref>) (“status hyperkineticus”). Triggers often lead to these exacerbations, and may include fever, intercurrent infections, heightened emotion, and stress. Attacks often arise in clusters and can last minutes to days or even weeks (Danti et al. <xref ref-type="bibr" rid="CR31">2017</xref>), often requiring admission to the intensive care unit. Patients with a predominant movement disorder phenotype often show mild cognitive impairment. In patients with <italic>GNAO1</italic>-related disease, brain magnetic resonance imaging is usually non-specific. However, a thin abnormal corpus callosum has been commonly reported (Danti et al. <xref ref-type="bibr" rid="CR31">2017</xref>). Atrophy of the basal ganglia and cerebral atrophy have also been described (Ananth et al. <xref ref-type="bibr" rid="CR3">2016</xref>; Sakamoto et al. <xref ref-type="bibr" rid="CR107">2017</xref>).</p>
</sec>
<sec id="Sec22">
<title>Treatment</title>
<p id="Par19">For <italic>GNAO1</italic>-related disorders, tetrabenazine, in particular in combination with neuroleptics (risperidone, haloperidol), appears to be effective for the baseline treatment of chorea (Ananth et al. <xref ref-type="bibr" rid="CR3">2016</xref>; Danti et al. <xref ref-type="bibr" rid="CR31">2017</xref>). However, clinicians should be cautious about side effects including acute dystonic reactions or malignant neuroleptic syndrome. Sakamoto reported a dramatic response to the anticonvulsant topiramate (7.5 mg/kg), an effect which might be attributed to the inhibitory action on voltage-gated Ca<sup>2+</sup> channels (Sakamoto et al. <xref ref-type="bibr" rid="CR107">2017</xref>). Episodic exacerbations of movement disorder are often pharmacoresistant. It is of utmost importance to urgently refer these patients to the intensive care unit for dystonia management (increment of dystonia medication dosages, sedation, paralysis), adequate hydration, and continuous monitoring of cardiorespiratory functions, temperature, and laboratory parameters including creatine kinase and renal function to reduce the risk of hyperthermia, renal failure, and rhabdomyolysis. In the case of pharmaco-refractory chorea or dyskinesia, especially when it becomes life-threatening, (emergency) placement of a deep brain stimulator (DBS) into the globus pallidus internus has often resulted in an excellent clinical response (Kulkarni et al. <xref ref-type="bibr" rid="CR65">2016</xref>; Yilmaz et al. <xref ref-type="bibr" rid="CR130">2016</xref>; Danti et al. <xref ref-type="bibr" rid="CR31">2017</xref>).</p>
</sec>
<sec id="Sec23">
<title>Genetics</title>
<p id="Par20">To date, <italic>GNAO1</italic> mutations have been identified in 43 individuals (Nakamura et al. <xref ref-type="bibr" rid="CR89">2013</xref>; Talvik et al. <xref ref-type="bibr" rid="CR120">2015</xref>; Law et al. <xref ref-type="bibr" rid="CR67">2015</xref>; Saitsu et al. <xref ref-type="bibr" rid="CR106">2016</xref>; Kulkarni et al. <xref ref-type="bibr" rid="CR65">2016</xref>; Marcé-Grau et al. <xref ref-type="bibr" rid="CR73">2016</xref>; Ananth et al. <xref ref-type="bibr" rid="CR3">2016</xref>; Yilmaz et al. <xref ref-type="bibr" rid="CR130">2016</xref>; Menke et al. <xref ref-type="bibr" rid="CR82">2016</xref>; Arya et al. <xref ref-type="bibr" rid="CR4">2017</xref>; Danti et al. <xref ref-type="bibr" rid="CR31">2017</xref>; Sakamoto et al. <xref ref-type="bibr" rid="CR107">2017</xref>; Schorling et al. <xref ref-type="bibr" rid="CR111">2017</xref>; Waak et al. <xref ref-type="bibr" rid="CR126">2017</xref>; Bruun et al. <xref ref-type="bibr" rid="CR12">2017</xref>). Pathogenic variants include mostly missense mutations, but also splice site mutations and one single case with a deletion (Nakamura et al. <xref ref-type="bibr" rid="CR89">2013</xref>; Danti et al. <xref ref-type="bibr" rid="CR31">2017</xref>). Mutations usually occur de novo, with somatic and gonadal mosaicism being described in several families (Nakamura et al. <xref ref-type="bibr" rid="CR89">2013</xref>; Yilmaz et al. <xref ref-type="bibr" rid="CR130">2016</xref>; Menke et al. <xref ref-type="bibr" rid="CR82">2016</xref>). The recurrence risk after one affected child has been estimated at 5–15% (Menke et al. <xref ref-type="bibr" rid="CR82">2016</xref>). In almost half of all patients, mutations arise at the highly conserved Arg209 and Glu246 residue indicating mutational hotspots. In vitro functional investigations into the molecular mechanism of 15 <italic>GNAO1</italic> pathogenic variants suggested genotype-phenotype correlations (Feng et al. <xref ref-type="bibr" rid="CR39">2017a</xref>). <italic>GNAO1</italic> loss of function variants was associated with epileptic encephalopathy, while gain of function variants was related to those causing predominantly movement disorders (Feng et al. <xref ref-type="bibr" rid="CR40">2017b</xref>). Menke and colleagues further reported that de novo missense mutations in the <italic>GNAO1</italic> codon 209 and 246 are predominantly associated with a movement disorder phenotype and developmental delay but without seizures (Menke et al. <xref ref-type="bibr" rid="CR82">2016</xref>). Based on a review of literature, Schorling et al. described a female preponderance for the EE phenotype, suggesting that predilection for epilepsy might be a gender-specific effect in <italic>GNAO1</italic>-related disorders (Schorling et al. <xref ref-type="bibr" rid="CR111">2017</xref>). The movement disorder phenotype appears to affect both sexes equally.</p>
</sec>
<sec id="Sec24">
<title>Molecular mechanisms</title>
<p id="Par21"><italic>GNAO1</italic> encodes the alpha-o subunit (Gα<sub>o</sub>) of G-proteins. G<sub>o</sub> are the most abundant G-proteins in brain tissue, particularly in neuronal synapses (Jiang and Bajpayee <xref ref-type="bibr" rid="CR56">2009</xref>). They regulate multiple intracellular effectors and associated signaling cascades including ion channels, enzymes, and small GTPases (Jiang and Bajpayee <xref ref-type="bibr" rid="CR56">2009</xref>). At the presynaptic level, G<sub>o</sub> proteins further mediate autoinhibitory effects of several neurotransmitters on their receptors (Brown and Sihra <xref ref-type="bibr" rid="CR11">2008</xref>). Gα<sub>o</sub> subunits are specifically involved in the inhibition of voltage-gate Ca<sup>2+</sup> channels and activation of inwardly rectifying K<sup>+</sup> channels (Simon et al. <xref ref-type="bibr" rid="CR114">1991</xref>; Schorling et al. <xref ref-type="bibr" rid="CR111">2017</xref>). Knockdown of Gα<sub>o</sub> proteins in mice (α<sub>o</sub>−/−) results in hyperactive behavior and motor abnormalities including generalized tremor and impaired motor control, as well as occasional seizures, hyperalgesia, and shortened lifespan (Jiang et al. <xref ref-type="bibr" rid="CR57">1998</xref>). A knock-in mutant mouse model (<italic>Gnao1</italic><sup><italic>+/G184S</italic></sup>) exhibits a severe seizure phenotype and premature death (Kehrl et al. <xref ref-type="bibr" rid="CR62">2014</xref>). The mutant mice exhibit elevated frequency of interictal epileptiform discharges on EEG but no overt brain morphology changes were seen.</p>
</sec>
</sec>
<sec id="Sec25">
<title>G proteinα<sub>olf</sub>-related dystonia</title>
<sec id="Sec26">
<title>Clinical presentation</title>
<p id="Par22">G proteinα<sub>olf</sub> (<italic>GNAL1</italic>)-related disorders were first reported in 2012, in adult-onset primary torsion dystonia (DYT 25, primary torsion dystonia) (Bressman et al. <xref ref-type="bibr" rid="CR10">1994</xref>; Fuchs et al. <xref ref-type="bibr" rid="CR44">2012</xref>). Disease onset occurs in the third or fourth decade of life. Dystonia is usually initially focal and affects predominantly the craniocervical region in most patients. With ongoing disease, dystonia progresses and typically leads to more extensive cervical or laryngeal involvement and less commonly truncal or limb involvement. Recently, Masuho et al. identified two affected individuals in a large consanguineous kindred who presented with childhood-onset dystonia (Masuho et al. <xref ref-type="bibr" rid="CR75">2016</xref>). Both siblings presented with hypertonia at the age of 1 year and developed generalized dystonia over time. Initial motor and language development was normal.</p>
</sec>
<sec id="Sec27">
<title>Treatment</title>
<p id="Par23">In <italic>GNAL1</italic>-associated dystonia, a therapeutic trial with levodopa was not beneficial (Bressman et al. <xref ref-type="bibr" rid="CR10">1994</xref>). Data on treatment with other anti-dystonic agents is scarce to date.</p>
</sec>
<sec id="Sec28">
<title>Genetics</title>
<p id="Par24"><italic>GNAL1</italic> mutations are inherited in an autosomal dominant manner with reduced penetrance (Carecchio et al. <xref ref-type="bibr" rid="CR18">2016</xref>). De novo heterozygous <italic>GNAL1</italic> mutations have also been described in three patients with seemingly sporadic dystonia and negative family history (Dobričić et al. <xref ref-type="bibr" rid="CR35">2014</xref>; Ziegan et al. <xref ref-type="bibr" rid="CR134">2014</xref>). Recently, autosomal recessive homozygous missense mutations in the <italic>GNAL1</italic> gene have been identified in a consanguineous kindred with childhood-onset dystonia (Masuho et al. <xref ref-type="bibr" rid="CR75">2016</xref>). In vitro functional assays have demonstrated attenuated DRD1 response for the nonsense mutant p.Ser293* and impaired association of the Gα<sub>olf</sub> subunit with the corresponding Gβγ subunit for the missense mutant p.Val137Met, thereby indicating loss of function.</p>
</sec>
<sec id="Sec29">
<title>Molecular mechanisms</title>
<p id="Par25"><italic>GNAL1</italic> encodes the stimulatory G-protein alpha subunit Gα<sub>olf</sub>. Gα<sub>olf</sub> belong to the stimulating G-proteins and couple “direct pathway” DRD1 and “indirect-pathway” A2 adenosine receptors to the activation of AC5 (Corvol et al. <xref ref-type="bibr" rid="CR26">2001</xref>; Vemula et al. <xref ref-type="bibr" rid="CR125">2013</xref>). Gα<sub>olf</sub> are enriched in striosomes, which are clusters of striatal MSNs that project to the SNpc (Crittenden and Graybiel <xref ref-type="bibr" rid="CR28">2011</xref>). An imbalance of the striatal striosome activity in relation to the surrounding matrix has been postulated to contribute to the development of hyperkinetic movement disorders (Fuchs et al. <xref ref-type="bibr" rid="CR44">2012</xref>). A <italic>Gnal</italic><sup><italic>+</italic></sup><italic>/</italic><sup><italic>−</italic></sup> knockout mouse model has been used to study L-DOPA-induced dyskinesia in parkinsonism (Alcacer et al. <xref ref-type="bibr" rid="CR1">2012</xref>). In the dopamine-denervated striatum, L-DOPA induces DRD1 signaling through the cAMP pathway including PKA and DARP-32. Striatonigral lesions of <italic>Gnal</italic><sup><italic>+</italic></sup><italic>/</italic><sup><italic>−</italic></sup> mice lead to upregulation of Gα<sub>olf</sub> and induce dyskinesia upon chronic treatment with L-DOPA.</p>
</sec>
</sec>
<sec id="Sec30">
<title>GPR88-related chorea</title>
<sec id="Sec31">
<title>Clinical presentation and genetics</title>
<p id="Par26">The phenotypic spectrum of <italic>GPR88</italic>-related movement disorder so far includes only four individuals from one consanguineous kindred (Alkufri et al. <xref ref-type="bibr" rid="CR2">2016</xref>). The female siblings presented with speech delay and learning disability and developed chorea at the age of 8–9 years. The movement disorder affected mainly the face and hands, but choreiform movements were also noted in the shoulders, pelvis, and thighs. Alkufri et al. identified a homozygous nonsense mutation in <italic>GPR88 gene</italic> encoding an orphan G-protein-coupled receptor (Alkufri et al. <xref ref-type="bibr" rid="CR2">2016</xref>).</p>
</sec>
<sec id="Sec32">
<title>Molecular mechanisms</title>
<p id="Par27">GPR88 is highly expressed in both DRD1- and DRD2-expressing MSNs of the striatum (Massart et al. <xref ref-type="bibr" rid="CR74">2009</xref>; Quintana et al. <xref ref-type="bibr" rid="CR100">2012</xref>). GPR88 deficiency in a knockout mouse model (<italic>Gpr88</italic><sup><italic>Cre</italic></sup><italic>/</italic><sup><italic>Cre</italic></sup>) leads to enhanced excitability of DRD1- and DRD2-expressing striatal MSNs owing to increased glutamate receptor phosphorylation and altered GABA<sub>A</sub> receptor composition (Quintana et al. <xref ref-type="bibr" rid="CR100">2012</xref>). The <italic>Gpr88</italic><sup><italic>Cre</italic></sup><italic>/</italic><sup><italic>Cre</italic></sup> mice show increased locomotion, hyperactivity in novel environment, and stereotypic behavior abnormalities reminiscent of striatal dysfunction (Meirsman et al. <xref ref-type="bibr" rid="CR79">2016</xref>).</p>
</sec>
</sec>
</sec>
<sec id="Sec33">
<title>Other genetic movement disorders associated with secondary postsynaptic dysfunction</title>
<sec id="Sec34">
<title>DYT1 early-onset dystonia</title>
<sec id="Sec35">
<title>Clinical presentation and genetics</title>
<p id="Par28">DYT1 dystonia is a hereditary early-onset movement disorder caused by mutations in <italic>TOR1A</italic> encoding the protein torsin A. Patients manifest with isolated dystonia in childhood or adolescence, usually without any other associated neurological abnormalities (Ozelius and Lubarr <xref ref-type="bibr" rid="CR94">1993</xref>). Though not part of the initial presentation, executive dysfunction and psychiatric comorbidities such as mood and anxiety disorders have been described in DYT1 dystonia (Jahanshahi <xref ref-type="bibr" rid="CR54">2017</xref>). In the early course of disease, dystonia usually affects one (usually lower) limb and is often related to specific actions (action-induced or task-specific dystonia). Over time, dystonia usually progresses and becomes segmental, multifocal, or generalized in 60–70% of all patients (Ozelius and Lubarr <xref ref-type="bibr" rid="CR94">1993</xref>). DYT1 dystonia shows an autosomal dominant mode of inheritance and manifests with reduced penetrance, estimated at 30%. The majority of patients harbor a three base pair deletion c.907_909delGAG deletion, though three additional in-frame deletions have been reported singly in other individuals (Ozelius and Lubarr <xref ref-type="bibr" rid="CR94">1993</xref>).</p>
</sec>
<sec id="Sec36">
<title>Molecular mechanisms</title>
<p id="Par29">Although the exact function of torsin A is yet to be fully elucidated, it is thought to shuttle between the endoplasmic reticulum (ER) and the nuclear envelope (NE) for several physiological functions including ER-associated degradation, dopamine release and metabolism, synaptic shuttling of mRNAs, and cytoskeleton dynamics (Ozelius and Lubarr <xref ref-type="bibr" rid="CR94">1993</xref>). Several studies have investigated the role of torsin A in dopamine neurotransmission in striatal neurons. Data from three different DYT transgenic mouse models suggest a role for presynaptic dysfunction in dopaminergic neurons owing to impaired dopamine release (Bao et al. <xref ref-type="bibr" rid="CR6">2010</xref>; Page et al. <xref ref-type="bibr" rid="CR95">2010</xref>). However, electrophysiological studies in striatal slice cultures from a transgenic DYT1 mouse model also revealed postsynaptic alterations. Activation of postsynaptic DRD2 resulted in a paradoxical excitatory effect in striatal cholinergic interneurons leading to inappropriate firing activity (Pisani et al. <xref ref-type="bibr" rid="CR97">2006</xref>). MSNs of transgenic mice showed decreased surface expression of postsynaptic DRD2 with deficient G-protein coupling (Napolitano et al. <xref ref-type="bibr" rid="CR90">2010</xref>). Further studies investigated a potential DRD2 trafficking defect due to reduced torsin A chaperone activity. This hypothesis was corroborated by data demonstrating a direct interaction between torsin A and DRD2 and PET imaging studies demonstrating decreased DRD2 availability in brains of DYT1 patients (Torres et al. <xref ref-type="bibr" rid="CR122">2004</xref>; Carbon et al. <xref ref-type="bibr" rid="CR17">2009</xref>).</p>
</sec>
</sec>
<sec id="Sec37">
<title>Monogenic forms of parkinsonism/Parkinson’s disease</title>
<sec id="Sec38">
<title>Clinical presentation and genetics</title>
<p id="Par30">Parkinson’s disease (PD) represents the second most common neurodegenerative disorder in adults and most commonly occurs sporadically (Kalia and Lang <xref ref-type="bibr" rid="CR60">2015</xref>). However, approximately 5–10% of patients have a monogenic form of the disease with an either autosomal recessive or dominant mode of inheritance (Lin and Farrer <xref ref-type="bibr" rid="CR70">2014</xref>). In these monogenic forms, disease onset typically occurs in childhood (juvenile onset parkinsonism, usually &lt; 20 years) or adulthood before the age of 40–45 (early-onset parkinsonism) (Puschmann <xref ref-type="bibr" rid="CR98">2013</xref>; Bonifati <xref ref-type="bibr" rid="CR9">2014</xref>). PD is neuropathologically characterized by progressive loss of nigrostriatal dopaminergic neurons leading to the typical clinical triad of bradykinesia/akinesia, rigidity, and tremor. In the monogenic early-onset forms of PD, additional neurological features including neurodevelopmental delay, intellectual disability, psychiatric comorbidities, and epilepsy are commonly reported. To date, several genes have been associated with juvenile, atypical parkinsonism (<italic>ATP13A2</italic>, <italic>PLA2G6</italic>, <italic>FBX07</italic>, <italic>DNAJC6</italic>, <italic>SYNJ1</italic>) and early-onset parkinsonism (<italic>SNCA</italic>, <italic>PARK2</italic>, <italic>PINK1</italic>, <italic>DJ1</italic>) (Bonifati <xref ref-type="bibr" rid="CR9">2014</xref>).</p>
</sec>
<sec id="Sec39">
<title>Molecular mechanisms</title>
<p id="Par31">Genes associated with early-onset parkinsonism are mainly involved in disruption of presynaptic function (Bonifati <xref ref-type="bibr" rid="CR9">2014</xref>). Pathogenic variants have been shown to impair protein trafficking, autophagy, and mitochondrial function culminating in loss of dopaminergic neurons (Lynch-Day et al. <xref ref-type="bibr" rid="CR72">2012</xref>; Pickrell and Youle <xref ref-type="bibr" rid="CR96">2015</xref>; Hunn et al. <xref ref-type="bibr" rid="CR51">2015</xref>). Many of the affected proteins in PD may also have other effects in different synaptic compartments, which remain yet to be fully elucidated. Indeed, in early-onset PD, there is emerging evidence for postsynaptic alterations that may contribute to the disease pathology. For example, Parkin, encoded by the gene <italic>PARK2</italic>, has been shown to localize to not only presynaptic but also postsynaptic terminals (Sassone et al. <xref ref-type="bibr" rid="CR108">2017</xref>). At the postsynaptic terminal, Parkin colocalizes with the postsynaptic density marker PSD-95. Through interaction with PSD-95, Parkin is suggested to regulate trafficking, anchoring, and clustering of membrane surface receptors (Sassone et al. <xref ref-type="bibr" rid="CR108">2017</xref>). Parkin is further involved in the mono-ubiquitination of PICK1, a synaptic scaffold protein that regulates the trafficking of several neurotransmitter receptors, ion channels, and enzymes (Joch et al. <xref ref-type="bibr" rid="CR58">2007</xref>). Further studies demonstrated that Parkin modulates postsynaptic glutamate receptors. Loss of Parkin leads to an increase in excitatory activity, which ultimately results in exitotoxic dopaminergic cell death (Sassone et al. <xref ref-type="bibr" rid="CR108">2017</xref>). Further studies are warranted to elucidate postsynaptic disease mechanisms in genetic early-onset PD. Overall, investigation of postsynaptic alterations in monogenic PD may provide insights into more common forms of PD.</p>
</sec>
</sec>
</sec>
<sec id="Sec40">
<title>Conclusion</title>
<p id="Par32">Over the past few years, a number of genetic movement disorders have been identified where defects in postsynaptic MSN function are thought to play a crucial role in disease pathogenesis. Mutations in genes such as <italic>ADCY5</italic>, <italic>PDE10A</italic>, <italic>GNAO1</italic>, <italic>GNAL1</italic>, and <italic>GPR88</italic> affect key proteins of the postsynaptic cAMP signaling pathway, which mediate the effects of dopaminergic neurotransmission in striatal MSNs. On a molecular level, loss or gain of function pathogenic variants differentially impact on the signaling cascade but result in hypo- or hyperfunctional dopaminergic signaling in striatal MSNs.</p>
<p id="Par33">From a clinical viewpoint, these genetic diseases which align to a common disease pathway also manifest a number of overlapping clinical features. All are characterized by prominent, early-onset movement disorders with hyperkinetic manifestations such as chorea and dyskinesia. Facial involvement is commonly reported in <italic>ADCY5-</italic>, <italic>PDE10A-</italic>, <italic>GNAO1-</italic>, and <italic>GPR88</italic>-related disorders. Despite these similarities, the course of disease and specific distinct phenotypic features may help to discriminate them clinically. Indeed, <italic>ADCY5-</italic> and <italic>PDE10A</italic>-related disorders seem to show a static or mildly progressive course, while <italic>GNAO1</italic>-related movement disorders are characterized by progressive chorea which can become life-threatening in some patients. Distinguishing clinical features may further include sleep-related phenomena and marked fluctuation in <italic>ADCY5</italic> disease, abnormal MRI features in dominant <italic>PDE10A</italic> disease, and severe exacerbations associated with autonomic dysfunction in patients with <italic>GNAO1</italic> mutations.</p>
<p id="Par34">Given these substantially overlapping phenotypes, establishing a definitive diagnosis is often not straightforward. Furthermore, with increasing patient diagnoses, the molecular and clinical spectrum is likely to further expand, with the identification of atypical disease phenotypes. Implementation of next-generation sequencing techniques in clinics has already translated into better diagnostics of these rare postsynaptic disorders. For many of these disorders, a diagnostic whole-exome approach or multiple-gene panel testing may be the most efficient method of reaching a confirmatory diagnosis. Despite these genetic advances, clinicians still face the enormous unmet need for disease-specific personalized therapies, as many of these disorders are pharmacoresistant and challenging to treat with conventional, currently available drugs. Precision medicine approaches, targeting the specific gene defect may provide a better long-term strategy to overcome this gap. Gene therapy and RNA manipulation techniques represent attractive new technologies to approach a patient’s specific genetic condition. Future identification of specific therapies targeting the cAMP pathway, a critical cellular signaling pathway in striatal MSNs, may revolutionize the treatment of these severe genetic movement disorders.</p>
</sec>
</body>
<back>
<notes notes-type="author-contribution">
<title>Author contributions</title>
<p>LA is the first author of this manuscript and drafted the manuscript. MAK is the last author of this manuscript, participated in drafting the manuscript, and gave substantial intellectual input. Both authors have seen and approved the manuscript.</p>
</notes>
<notes notes-type="funding-information">
<title>Funding</title>
<p>Prof Kurian is funded by an NIHR Research Professorship and the Wellcome Trust Wellcome Trust, as well as through a project grant from the Rosetrees Trust. Dr. Abela is funded by a Swiss National Foundation Advanced Postdoc. Mobility fellowship.</p>
</notes>
<notes notes-type="COI-statement">
<sec id="FPar1">
<title>Conflict of interest</title>
<p>Prof. Manju Kurian and Dr. Lucia Abela declare that they have no conflict of interest.</p>
</sec>
<sec id="FPar2">
<title>Informed consent</title>
<p>Not applicable</p>
</sec>
<sec id="FPar3">
<title>Animal right</title>
<p>Not applicable</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alcacer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Santini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Valjent</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>G olf mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-Dihydroxyphenylalanine-induced dyskinesia</article-title>
<source/>J Neurosci
          <year>2012</year>
<volume>32</volume>
<fpage>5900</fpage>
<lpage>5910</lpage>
<pub-id pub-id-type="pmid">22539851</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alkufri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Shaag</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Abu-Libdeh</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Elpeleg</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Deleterious mutation in GPR88 is associated with chorea, speech delay, and learning disabilities</article-title>
<source/>Neurol Genet
          <year>2016</year>
<volume>2</volume>
<fpage>e64</fpage>
<pub-id pub-id-type="pmid">27123486</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ananth</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Robichaux-Viehoever</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y-M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical course of six children with GNAO1 mutations causing a severe and distinctive movement disorder</article-title>
<source/>Pediatr Neurol
          <year>2016</year>
<volume>59</volume>
<fpage>81</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="pmid">27068059</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arya</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Spaeth</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>DL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GNAO1-associated epileptic encephalopathy and movement disorders: c.607G&amp;gt; a variant represents a probable mutation hotspot with a distinct phenotype</article-title>
<source/>Epileptic Disord
          <year>2017</year>
<volume>19</volume>
<fpage>67</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="pmid">28202424</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baker</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Grozeva</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of a human synaptotagmin-1 mutation that perturbs synaptic vesicle cycling</article-title>
<source/>J Clin Invest
          <year>2015</year>
<volume>125</volume>
<fpage>1670</fpage>
<lpage>1678</lpage>
<pub-id pub-id-type="pmid">25705886</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>RH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dysregulation of striatal dopamine release in a mouse model of dystonia</article-title>
<source/>J Neurochem
          <year>2010</year>
<volume>114</volume>
<fpage>1781</fpage>
<lpage>1791</lpage>
<pub-id pub-id-type="pmid">20626557</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bayés</surname>
<given-names>À</given-names>
</name>
<name>
<surname>van de Lagemaat</surname>
<given-names>LN</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>MO</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of the proteome, diseases and evolution of the human postsynaptic density</article-title>
<source/>Nat Neurosci
          <year>2011</year>
<volume>14</volume>
<fpage>19</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="pmid">21170055</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beaumont</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phosphodiesterase 10A inhibition improves cortico-basal ganglia function in Huntington’s disease models</article-title>
<source/>Neuron
          <year>2016</year>
<volume>92</volume>
<fpage>1220</fpage>
<lpage>1237</lpage>
<pub-id pub-id-type="pmid">27916455</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Genetics of Parkinson’s disease—state of the art, 2013</article-title>
<source/>Parkinsonism Relat Disord
          <year>2014</year>
<volume>20</volume>
<fpage>S23</fpage>
<lpage>S28</lpage>
<pub-id pub-id-type="pmid">24262182</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bressman</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Heiman</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Nygaard</surname>
<given-names>TG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A study of idiopathic torsion dystonia in a non-Jewish family: evidence for genetic heterogeneity</article-title>
<source/>Neurology
          <year>1994</year>
<volume>44</volume>
<fpage>283</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="pmid">8309575</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<mixed-citation publication-type="other">Brown DA, Sihra TS (2008) Presynaptic signaling by heterotrimeric G-proteins. Handb Exp Pharmacol (184):207–260. 10.1007/978-3-540-74805-2_8</mixed-citation>
</ref>
<ref id="CR12">
<mixed-citation publication-type="other">Bruun TUJ, DesRoches C-L, Wilson D et al (2017) Prospective cohort study for identification of underlying genetic causes in neonatal encephalopathy using whole-exome sequencing. Genet Med. 10.1038/gim.2017.129</mixed-citation>
</ref>
<ref id="CR13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calabresi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pisani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rothwell</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hyperkinetic disorders and loss of synaptic downscaling</article-title>
<source/>Nat Neurosci
          <year>2016</year>
<volume>19</volume>
<fpage>868</fpage>
<lpage>875</lpage>
<pub-id pub-id-type="pmid">27351172</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caleo</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Epilepsy: synapses stuck in childhood</article-title>
<source/>Nat Med
          <year>2009</year>
<volume>15</volume>
<fpage>1126</fpage>
<lpage>1127</lpage>
<pub-id pub-id-type="pmid">19812567</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wegrzynowicz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Santivañez-Perez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Grazia Spillantini</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Synaptic failure and α-synuclein</article-title>
<source/>Mov Disord
          <year>2016</year>
<volume>31</volume>
<fpage>169</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="pmid">26790375</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carapito</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Untrau</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A de novo ADCY5 mutation causes early-onset autosomal dominant chorea and dystonia</article-title>
<source/>Mov Disord
          <year>2015</year>
<volume>30</volume>
<fpage>423</fpage>
<lpage>427</lpage>
<pub-id pub-id-type="pmid">25545163</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carbon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Niethammer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Abnormal striatal and thalamic dopamine neurotransmission: genotype-related features of dystonia</article-title>
<source/>Neurology
          <year>2009</year>
<volume>72</volume>
<fpage>2097</fpage>
<lpage>2103</lpage>
<pub-id pub-id-type="pmid">19528516</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carecchio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Panteghini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Reale</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel GNAL mutation with intra-familial clinical heterogeneity: expanding the phenotype</article-title>
<source/>Parkinsonism Relat Disord
          <year>2016</year>
<volume>23</volume>
<fpage>66</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="pmid">26725140</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carecchio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mencacci</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Iodice</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ADCY5-related movement disorders: frequency, disease course and phenotypic variability in a cohort of paediatric patients</article-title>
<source/>Parkinsonism Relat Disord
          <year>2017</year>
<volume>41</volume>
<fpage>37</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">28511835</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casillas-Espinosa</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>Regulators of synaptic transmission: roles in the pathogenesis and treatment of epilepsy</article-title>
<source/>Epilepsia
          <year>2012</year>
<volume>53</volume>
<fpage>41</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">23216578</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>FCF</given-names>
</name>
<name>
<surname>Westenberger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dale</surname>
<given-names>RC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phenotypic insights into ADCY5-associated disease</article-title>
<source/>Mov Disord
          <year>2016</year>
<volume>31</volume>
<fpage>1033</fpage>
<lpage>1040</lpage>
<pub-id pub-id-type="pmid">27061943</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y-Z</given-names>
</name>
<name>
<surname>Matsushita</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autosomal dominant familial dyskinesia and facial myokymia: single exome sequencing identifies a mutation in adenylyl cyclase 5</article-title>
<source/>Arch Neurol
          <year>2012</year>
<volume>69</volume>
<fpage>630</fpage>
<lpage>635</lpage>
<pub-id pub-id-type="pmid">22782511</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y-Z</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D-H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gain-of-function ADCY5 mutations in familial dyskinesia with facial myokymia</article-title>
<source/>Ann Neurol
          <year>2014</year>
<volume>75</volume>
<fpage>542</fpage>
<lpage>549</lpage>
<pub-id pub-id-type="pmid">24700542</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>D-H</given-names>
</name>
<name>
<surname>Méneret</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>JR</given-names>
</name>
<etal></etal>
</person-group>
<article-title><italic>ADCY5</italic>-related dyskinesia</article-title>
<source/>Neurology
          <year>2015</year>
<volume>85</volume>
<fpage>2026</fpage>
<lpage>2035</lpage>
<pub-id pub-id-type="pmid">26537056</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chuhma</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Hen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rayport</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Functional connectome of the striatal medium spiny neuron</article-title>
<source/>J Neurosci
          <year>2011</year>
<volume>31</volume>
<fpage>1183</fpage>
<lpage>1192</lpage>
<pub-id pub-id-type="pmid">21273403</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corvol</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Studler</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Schonn</surname>
<given-names>JS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Galpha(olf) is necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum</article-title>
<source/>J Neurochem
          <year>2001</year>
<volume>76</volume>
<fpage>1585</fpage>
<lpage>1588</lpage>
<pub-id pub-id-type="pmid">11238742</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coskran</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Morton</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Menniti</surname>
<given-names>FS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species</article-title>
<source/>J Histochem Cytochem
          <year>2006</year>
<volume>54</volume>
<fpage>1205</fpage>
<lpage>1213</lpage>
<pub-id pub-id-type="pmid">16864896</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crittenden</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Graybiel</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Basal ganglia disorders associated with imbalances in the striatal striosome and matrix compartments</article-title>
<source/>Front Neuroanat
          <year>2011</year>
<volume>5</volume>
<fpage>59</fpage>
<pub-id pub-id-type="pmid">21941467</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crocker-Buque</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Currie</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Luz</surname>
<given-names>LL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered thalamocortical development in the SAP102 knockout model of intellectual disability</article-title>
<source/>Hum Mol Genet
          <year>2016</year>
<volume>25</volume>
<fpage>4052</fpage>
<lpage>4061</lpage>
<pub-id pub-id-type="pmid">27466188</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dan’ura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kurokawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inhibition of rat brain adenylate cyclase activity by benzodiazepine through the effects on Gi and catalytic proteins</article-title>
<source/>Life Sci
          <year>1988</year>
<volume>42</volume>
<fpage>469</fpage>
<lpage>475</lpage>
<pub-id pub-id-type="pmid">2828793</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Danti</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Galosi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Romani</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title><italic>GNAO1</italic> encephalopathy</article-title>
<source/>Neurol Genet
          <year>2017</year>
<volume>3</volume>
<fpage>e143</fpage>
<pub-id pub-id-type="pmid">28357411</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Rubeis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>AP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Synaptic, transcriptional and chromatin genes disrupted in autism</article-title>
<source/>Nature
          <year>2014</year>
<volume>515</volume>
<fpage>209</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="pmid">25363760</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeLong</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Wichmann</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Circuits and circuit disorders of the basal ganglia</article-title>
<source/>Arch Neurol
          <year>2007</year>
<volume>64</volume>
<fpage>20</fpage>
<pub-id pub-id-type="pmid">17210805</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diggle</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Sukoff Rizzo</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Popiolek</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Biallelic mutations in PDE10A lead to loss of striatal PDE10A and a hyperkinetic movement disorder with onset in infancy</article-title>
<source/>Am J Hum Genet
          <year>2016</year>
<volume>98</volume>
<fpage>735</fpage>
<lpage>743</lpage>
<pub-id pub-id-type="pmid">27058446</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dobričić</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kresojević</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Westenberger</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutation in the <italic>GNAL</italic> gene causing seemingly sporadic dystonia in a Serbian patient</article-title>
<source/>Mov Disord
          <year>2014</year>
<volume>29</volume>
<fpage>1190</fpage>
<lpage>1193</lpage>
<pub-id pub-id-type="pmid">24729450</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Douglas</surname>
<given-names>AGL</given-names>
</name>
<name>
<surname>Andreoletti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Talbot</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ADCY5-related dyskinesia presenting as familial myoclonus-dystonia</article-title>
<source/>Neurogenetics
          <year>2017</year>
<volume>18</volume>
<fpage>111</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="pmid">28229249</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dy</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>FCF</given-names>
</name>
<name>
<surname>Jesus</surname>
<given-names>SD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Treatment of ADCY5-associated dystonia, chorea, and hyperkinetic disorders with deep brain stimulation: a multicenter case series</article-title>
<source/>J Child Neurol
          <year>2016</year>
<volume>31</volume>
<fpage>1027</fpage>
<lpage>1035</lpage>
<pub-id pub-id-type="pmid">27052971</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<mixed-citation publication-type="other">Esposito S, Carecchio M, Tonduti D et al (2017) A <italic>PDE10A</italic> de novo mutation causes childhood-onset chorea with diurnal fluctuations. Mov Disord. 10.1002/mds.27175</mixed-citation>
</ref>
<ref id="CR39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sjögren</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Karaj</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Movement disorder in <italic>GNAO1</italic> encephalopathy associated with gain-of-function mutations</article-title>
<source/>Neurology
          <year>2017</year>
<volume>89</volume>
<fpage>762</fpage>
<lpage>770</lpage>
<pub-id pub-id-type="pmid">28747448</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<mixed-citation publication-type="other">Feng H, Sjögren B, Karaj B et al (2017b) Movement disorder in <italic>GNAO1</italic> encephalopathy associated with gain-of-function mutations. Neurology. 10.1212/WNL.0000000000004262</mixed-citation>
</ref>
<ref id="CR41">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Raskind</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wolff</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Familial dyskinesia and facial myokymia (FDFM): a novel movement disorder</article-title>
<source/>Ann Neurol
          <year>2001</year>
<volume>49</volume>
<fpage>486</fpage>
<lpage>492</lpage>
<pub-id pub-id-type="pmid">11310626</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fisone</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Håkansson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Borgkvist</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Santini</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Signaling in the basal ganglia: postsynaptic and presynaptic mechanisms</article-title>
<source/>Physiol Behav
          <year>2007</year>
<volume>92</volume>
<fpage>8</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">17585965</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fromer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pocklington</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Kavanagh</surname>
<given-names>DH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutations in schizophrenia implicate synaptic networks</article-title>
<source/>Nature
          <year>2014</year>
<volume>506</volume>
<fpage>179</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="pmid">24463507</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuchs</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Saunders-Pullman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Masuho</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in GNAL cause primary torsion dystonia</article-title>
<source/>Nat Genet
          <year>2012</year>
<volume>45</volume>
<fpage>88</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="pmid">23222958</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerber</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Squires</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Hepler</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Roles for regulator of G protein signaling proteins in synaptic signaling and plasticity</article-title>
<source/>Mol Pharmacol
          <year>2016</year>
<volume>89</volume>
<fpage>273</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="pmid">26655302</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giovedí</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Corradi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fassio</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Benfenati</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Involvement of synaptic genes in the pathogenesis of autism spectrum disorders: the case of synapsins</article-title>
<source/>Front Pediatr
          <year>2014</year>
<volume>2</volume>
<fpage>94</fpage>
<pub-id pub-id-type="pmid">25237665</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guarnieri</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Pozzi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Raimondi</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel SYN1 missense mutation in non-syndromic X-linked intellectual disability affects synaptic vesicle life cycle, clustering and mobility</article-title>
<source/>Hum Mol Genet
          <year>2017</year>
<volume>26</volume>
<fpage>4699</fpage>
<lpage>4714</lpage>
<pub-id pub-id-type="pmid">28973667</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamdan</surname>
<given-names>FF</given-names>
</name>
<name>
<surname>Piton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gauthier</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo <italic>STXBP1</italic> mutations in mental retardation and nonsyndromic epilepsy</article-title>
<source/>Ann Neurol
          <year>2009</year>
<volume>65</volume>
<fpage>748</fpage>
<lpage>753</lpage>
<pub-id pub-id-type="pmid">19557857</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanoune</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pouille</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tzavara</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Adenylyl cyclases: structure, regulation and function in an enzyme superfamily</article-title>
<source/>Mol Cell Endocrinol
          <year>1997</year>
<volume>128</volume>
<fpage>179</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="pmid">9140089</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hervé</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Le Moine</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Corvol</surname>
<given-names>JC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Galpha(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum</article-title>
<source/>J Neurosci
          <year>2001</year>
<volume>21</volume>
<fpage>4390</fpage>
<lpage>4399</lpage>
<pub-id pub-id-type="pmid">11404425</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunn</surname>
<given-names>BHM</given-names>
</name>
<name>
<surname>Cragg</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Bolam</surname>
<given-names>JP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impaired intracellular trafficking defines early Parkinson’s disease</article-title>
<source/>Trends Neurosci
          <year>2015</year>
<volume>38</volume>
<fpage>178</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="pmid">25639775</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hyman</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>Neurotransmitters</article-title>
<source/>Curr Biol
          <year>2005</year>
<volume>15</volume>
<fpage>R154</fpage>
<lpage>R158</lpage>
<pub-id pub-id-type="pmid">15753022</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwamoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Okumura</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Iwatsubo</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Motor dysfunction in type 5 adenylyl cyclase-null mice</article-title>
<source/>J Biol Chem
          <year>2003</year>
<volume>278</volume>
<fpage>16936</fpage>
<lpage>16940</lpage>
<pub-id pub-id-type="pmid">12665504</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jahanshahi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Neuropsychological and neuropsychiatric features of idiopathic and DYT1 dystonia and the impact of medical and surgical treatment</article-title>
<source/>Arch Clin Neuropsychol
          <year>2017</year>
<volume>32</volume>
<fpage>888</fpage>
<lpage>905</lpage>
<pub-id pub-id-type="pmid">29077804</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Um</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Coexistence of glutamatergic spine synapses and shaft synapses in substantia nigra dopamine neurons</article-title>
<source/>Sci Rep
          <year>2015</year>
<volume>5</volume>
<fpage>14773</fpage>
<pub-id pub-id-type="pmid">26435058</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bajpayee</surname>
<given-names>NS</given-names>
</name>
</person-group>
<article-title>Molecular mechanisms of go signaling</article-title>
<source/>Neurosignals
          <year>2009</year>
<volume>17</volume>
<fpage>23</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">19212138</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gold</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Boulay</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Multiple neurological abnormalities in mice deficient in the G protein Go</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1998</year>
<volume>95</volume>
<fpage>3269</fpage>
<lpage>3274</lpage>
<pub-id pub-id-type="pmid">9501252</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ase</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>CX-Q</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels</article-title>
<source/>Mol Biol Cell
          <year>2007</year>
<volume>18</volume>
<fpage>3105</fpage>
<lpage>3118</lpage>
<pub-id pub-id-type="pmid">17553932</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johannesen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Marini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pfeffer</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phenotypic spectrum of <italic>GABRA1</italic></article-title>
<source/>Neurology
          <year>2016</year>
<volume>87</volume>
<fpage>1140</fpage>
<lpage>1151</lpage>
<pub-id pub-id-type="pmid">27521439</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalia</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>AE</given-names>
</name>
</person-group>
<article-title>Parkinson’s disease</article-title>
<source/>Lancet
          <year>2015</year>
<volume>386</volume>
<fpage>896</fpage>
<lpage>912</lpage>
<pub-id pub-id-type="pmid">25904081</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Voleti</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hajszan</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Decreased expression of synapse-related genes and loss of synapses in major depressive disorder</article-title>
<source/>Nat Med
          <year>2012</year>
<volume>18</volume>
<fpage>1413</fpage>
<lpage>1417</lpage>
<pub-id pub-id-type="pmid">22885997</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kehrl</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Sahaya</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dalton</surname>
<given-names>HM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gain-of-function mutation in Gnao1: a murine model of epileptiform encephalopathy (EIEE17)?</article-title>
<source/>Mamm Genome
          <year>2014</year>
<volume>25</volume>
<fpage>202</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="pmid">24700286</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kingwell</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Epilepsy: GRIN2A mutations identified as key genetic drivers of epilepsy–aphasia spectrum disorders</article-title>
<source/>Nat Rev Neurol
          <year>2013</year>
<volume>9</volume>
<fpage>541</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="pmid">23999465</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kononenko</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Haucke</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Molecular mechanisms of presynaptic membrane retrieval and synaptic vesicle reformation</article-title>
<source/>Neuron
          <year>2015</year>
<volume>85</volume>
<fpage>484</fpage>
<lpage>496</lpage>
<pub-id pub-id-type="pmid">25654254</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kulkarni</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bhardwaj</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Progressive movement disorder in brothers carrying a GNAO1 mutation responsive to deep brain stimulation</article-title>
<source/>J Child Neurol
          <year>2016</year>
<volume>31</volume>
<fpage>211</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="pmid">26060304</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurian</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Dale</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>Movement disorders presenting in childhood</article-title>
<source/>Contin Lifelong Learn Neurol
          <year>2016</year>
<volume>22</volume>
<fpage>1159</fpage>
<lpage>1185</lpage>
</element-citation>
</ref>
<ref id="CR67">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Law</surname>
<given-names>C-Y</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>ST-L</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>SY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical whole-exome sequencing reveals a novel missense pathogenic variant of GNAO1 in a patient with infantile-onset epilepsy</article-title>
<source/>Clin Chim Acta
          <year>2015</year>
<volume>451</volume>
<fpage>292</fpage>
<lpage>296</lpage>
<pub-id pub-id-type="pmid">26485252</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>K-W</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>J-H</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>IY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase</article-title>
<source/>J Neurosci
          <year>2002</year>
<volume>22</volume>
<fpage>7931</fpage>
<lpage>7940</lpage>
<pub-id pub-id-type="pmid">12223546</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lepeta</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lourenco</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Schweitzer</surname>
<given-names>BC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Synaptopathies: synaptic dysfunction in neurological disorders—a review from students to students</article-title>
<source/>J Neurochem
          <year>2016</year>
<volume>138</volume>
<fpage>785</fpage>
<lpage>805</lpage>
<pub-id pub-id-type="pmid">27333343</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Farrer</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Genetics and genomics of Parkinson’s disease</article-title>
<source/>Genome Med
          <year>2014</year>
<volume>6</volume>
<fpage>48</fpage>
<pub-id pub-id-type="pmid">25061481</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipstein</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Verhoeven-Duif</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Michelassi</surname>
<given-names>FE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Synaptic UNC13A protein variant causes increased neurotransmission and dyskinetic movement disorder</article-title>
<source/>J Clin Invest
          <year>2017</year>
<volume>127</volume>
<fpage>1005</fpage>
<lpage>1018</lpage>
<pub-id pub-id-type="pmid">28192369</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lynch-Day</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The role of autophagy in Parkinson’s disease</article-title>
<source/>Cold Spring Harb Perspect Med
          <year>2012</year>
<volume>2</volume>
<fpage>a009357</fpage>
<lpage>a009357</lpage>
<pub-id pub-id-type="pmid">22474616</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marcé-Grau</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dalton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>López-Pisón</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GNAO1 encephalopathy: further delineation of a severe neurodevelopmental syndrome affecting females</article-title>
<source/>Orphanet J Rare Dis
          <year>2016</year>
<volume>11</volume>
<fpage>38</fpage>
<pub-id pub-id-type="pmid">27072799</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Massart</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Guilloux</surname>
<given-names>J-P</given-names>
</name>
<name>
<surname>Mignon</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents</article-title>
<source/>Eur J Neurosci
          <year>2009</year>
<volume>30</volume>
<fpage>397</fpage>
<lpage>414</lpage>
<pub-id pub-id-type="pmid">19656174</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masuho</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Homozygous <italic>GNAL</italic> mutation associated with familial childhood-onset generalized dystonia</article-title>
<source/>Neurol Genet
          <year>2016</year>
<volume>2</volume>
<fpage>e78</fpage>
<pub-id pub-id-type="pmid">27222887</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matikainen-Ankney</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Kezunovic</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mesias</surname>
<given-names>RE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered development of synapse structure and function in striatum caused by Parkinson’s disease-linked LRRK2-G2019S mutation</article-title>
<source/>J Neurosci
          <year>2016</year>
<volume>36</volume>
<fpage>7128</fpage>
<lpage>7141</lpage>
<pub-id pub-id-type="pmid">27383589</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuoka</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Defer</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Differential expression of type I, II, and V adenylyl cyclase gene in the postnatal developing rat brain</article-title>
<source/>J Neurochem
          <year>1997</year>
<volume>68</volume>
<fpage>498</fpage>
<lpage>506</lpage>
<pub-id pub-id-type="pmid">9003034</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meijer</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Miravite</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kopell</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Lubarr</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Deep brain stimulation in an additional patient with <italic>ADCY5</italic>-related movement disorder</article-title>
<source/>J Child Neurol
          <year>2017</year>
<volume>32</volume>
<fpage>438</fpage>
<lpage>439</lpage>
<pub-id pub-id-type="pmid">27920267</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meirsman</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Le Merrer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pellissier</surname>
<given-names>LP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mice lacking GPR88 show motor deficit, improved spatial learning, and low anxiety reversed by delta opioid antagonist</article-title>
<source/>Biol Psychiatry
          <year>2016</year>
<volume>79</volume>
<fpage>917</fpage>
<lpage>927</lpage>
<pub-id pub-id-type="pmid">26188600</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mencacci</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Erro</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wiethoff</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title><italic>ADCY5</italic> mutations are another cause of benign hereditary chorea</article-title>
<source/>Neurology
          <year>2015</year>
<volume>85</volume>
<fpage>80</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="pmid">26085604</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mencacci</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Kamsteeg</surname>
<given-names>E-J</given-names>
</name>
<name>
<surname>Nakashima</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutations in PDE10A cause childhood-onset chorea with bilateral striatal lesions</article-title>
<source/>Am J Hum Genet
          <year>2016</year>
<volume>98</volume>
<fpage>763</fpage>
<lpage>771</lpage>
<pub-id pub-id-type="pmid">27058447</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menke</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Engelen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Alders</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recurrent GNAO1 mutations associated with developmental delay and a movement disorder</article-title>
<source/>J Child Neurol
          <year>2016</year>
<volume>31</volume>
<fpage>1598</fpage>
<lpage>1601</lpage>
<pub-id pub-id-type="pmid">27625011</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menniti</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Chappie</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Humphrey</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia</article-title>
<source/>Curr Opin Investig Drugs
          <year>2007</year>
<volume>8</volume>
<fpage>54</fpage>
<lpage>59</lpage>
</element-citation>
</ref>
<ref id="CR84">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mircsof</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Langouët</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rio</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in NONO lead to syndromic intellectual disability and inhibitory synaptic defects</article-title>
<source/>Nat Neurosci
          <year>2015</year>
<volume>18</volume>
<fpage>1731</fpage>
<lpage>1736</lpage>
<pub-id pub-id-type="pmid">26571461</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morigaki</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Goto</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Postsynaptic density protein 95 in the striosome and matrix compartments of the human neostriatum</article-title>
<source/>Front Neuroanat
          <year>2015</year>
<volume>9</volume>
<fpage>154</fpage>
<pub-id pub-id-type="pmid">26648848</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<mixed-citation publication-type="other">Musardo S, Marcello E (2017) Synaptic dysfunction in Alzheimer’s disease: from the role of amyloid β-peptide to the α-secretase ADAM10. Eur J Pharmacol. 10.1016/j.ejphar.2017.06.018</mixed-citation>
</ref>
<ref id="CR87">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Myers</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Stong</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mountier</surname>
<given-names>EI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutations in PPP3CA cause severe neurodevelopmental disease with seizures</article-title>
<source/>Am J Hum Genet
          <year>2017</year>
<volume>101</volume>
<fpage>516</fpage>
<lpage>524</lpage>
<pub-id pub-id-type="pmid">28942967</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nairn</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Svenningsson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nishi</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The role of DARPP-32 in the actions of drugs of abuse</article-title>
<source/>Neuropharmacology
          <year>2004</year>
<volume>47</volume>
<fpage>14</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">15464122</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakamura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kodera</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Akita</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutations in GNAO1, encoding a Gαo subunit of heterotrimeric G proteins, cause epileptic encephalopathy</article-title>
<source/>Am J Hum Genet
          <year>2013</year>
<volume>93</volume>
<fpage>496</fpage>
<lpage>505</lpage>
<pub-id pub-id-type="pmid">23993195</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Napolitano</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pasqualetti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Usiello</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia</article-title>
<source/>Neurobiol Dis
          <year>2010</year>
<volume>38</volume>
<fpage>434</fpage>
<lpage>445</lpage>
<pub-id pub-id-type="pmid">20227500</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niturad</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Lev</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kalscheuer</surname>
<given-names>VM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rare GABRA3 variants are associated with epileptic seizures</article-title>
<source/>encephalopathy and dysmorphic features Brain
          <year>2017</year>
<volume>140</volume>
<fpage>2879</fpage>
<lpage>2894</lpage>
<pub-id pub-id-type="pmid">29053855</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oldham</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Hamm</surname>
<given-names>HE</given-names>
</name>
</person-group>
<article-title>Heterotrimeric G protein activation by G-protein-coupled receptors</article-title>
<source/>Nat Rev Mol Cell Biol
          <year>2008</year>
<volume>9</volume>
<fpage>60</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="pmid">18043707</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olgiati</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Quadri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Genetics of movement disorders in the next-generation sequencing era</article-title>
<source/>Mov Disord
          <year>2016</year>
<volume>31</volume>
<fpage>458</fpage>
<lpage>470</lpage>
<pub-id pub-id-type="pmid">26899883</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<mixed-citation publication-type="other">Ozelius L, Lubarr N (1993) DYT1 early-onset isolated dystonia. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A (eds) GeneReviews® [Internet]. University of Washington, Seattle </mixed-citation>
</ref>
<ref id="CR95">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Page</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Andre</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cell-autonomous alteration of dopaminergic transmission by wild type and mutant (DeltaE) TorsinA in transgenic mice</article-title>
<source/>Neurobiol Dis
          <year>2010</year>
<volume>39</volume>
<fpage>318</fpage>
<lpage>326</lpage>
<pub-id pub-id-type="pmid">20460154</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pickrell</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Youle</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson’s disease</article-title>
<source/>Neuron
          <year>2015</year>
<volume>85</volume>
<fpage>257</fpage>
<lpage>273</lpage>
<pub-id pub-id-type="pmid">25611507</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pisani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Martella</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tscherter</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia</article-title>
<source/>Neurobiol Dis
          <year>2006</year>
<volume>24</volume>
<fpage>318</fpage>
<lpage>325</lpage>
<pub-id pub-id-type="pmid">16934985</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puschmann</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Monogenic Parkinson’s disease and parkinsonism: clinical phenotypes and frequencies of known mutations</article-title>
<source/>Park Relat Disord
          <year>2013</year>
<volume>19</volume>
<fpage>407</fpage>
<lpage>415</lpage>
</element-citation>
</ref>
<ref id="CR99">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quartarone</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pisani</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Abnormal plasticity in dystonia: disruption of synaptic homeostasis</article-title>
<source/>Neurobiol Dis
          <year>2011</year>
<volume>42</volume>
<fpage>162</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="pmid">21168494</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quintana</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sanz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lack of GPR88 enhances medium spiny neuron activity and alters motor- and cue-dependent behaviors</article-title>
<source/>Nat Neurosci
          <year>2012</year>
<volume>15</volume>
<fpage>1547</fpage>
<lpage>1555</lpage>
<pub-id pub-id-type="pmid">23064379</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raheem</surname>
<given-names>IT</given-names>
</name>
<name>
<surname>Schreier</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Fuerst</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia</article-title>
<source/>Bioorg Med Chem Lett
          <year>2016</year>
<volume>26</volume>
<fpage>126</fpage>
<lpage>132</lpage>
<pub-id pub-id-type="pmid">26602277</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reale</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Panteghini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Carecchio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Garavaglia</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>The relevance of gene panels in movement disorders diagnosis: a lab perspective</article-title>
<source/>Eur J Paediatr Neurol
          <year>2018</year>
<volume>22</volume>
<fpage>285</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="pmid">29396176</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rizo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The synaptic vesicle release machinery</article-title>
<source/>Annu Rev Biophys
          <year>2015</year>
<volume>44</volume>
<fpage>339</fpage>
<lpage>367</lpage>
<pub-id pub-id-type="pmid">26098518</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rizzoli</surname>
<given-names>SO</given-names>
</name>
<name>
<surname>Betz</surname>
<given-names>WJ</given-names>
</name>
</person-group>
<article-title>Synaptic vesicle pools</article-title>
<source/>Nat Rev Neurosci
          <year>2005</year>
<volume>6</volume>
<fpage>57</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="pmid">15611727</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sadybekov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Arnesano</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An autism spectrum disorder-related de novo mutation hotspot discovered in the GEF1 domain of Trio</article-title>
<source/>Nat Commun
          <year>2017</year>
<volume>8</volume>
<fpage>601</fpage>
<pub-id pub-id-type="pmid">28928363</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saitsu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fukai</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ben-Zeev</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phenotypic spectrum of GNAO1 variants: epileptic encephalopathy to involuntary movements with severe developmental delay</article-title>
<source/>Eur J Hum Genet
          <year>2016</year>
<volume>24</volume>
<fpage>129</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="pmid">25966631</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakamoto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Monden</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fukai</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A case of severe movement disorder with GNAO1 mutation responsive to topiramate</article-title>
<source/>Brain and Development
          <year>2017</year>
<volume>39</volume>
<fpage>439</fpage>
<lpage>443</lpage>
<pub-id pub-id-type="pmid">27916449</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<mixed-citation publication-type="other">Sassone J, Serratto G, Valtorta F et al (2017) The synaptic function of parkin. Brain. 10.1093/brain/awx006</mixed-citation>
</ref>
<ref id="CR109">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schirinzi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Madeo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Martella</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Early synaptic dysfunction in Parkinson’s disease: insights from animal models</article-title>
<source/>Mov Disord
          <year>2016</year>
<volume>31</volume>
<fpage>802</fpage>
<lpage>813</lpage>
<pub-id pub-id-type="pmid">27193205</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Chapin</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Cianfrogna</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia</article-title>
<source/>J Pharmacol Exp Ther
          <year>2008</year>
<volume>325</volume>
<fpage>681</fpage>
<lpage>690</lpage>
<pub-id pub-id-type="pmid">18287214</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<mixed-citation publication-type="other">Schorling D, Dietel T, Evers C et al (2017) Expanding phenotype of de novo mutations in GNAO1: four new cases and review of literature. Neuropediatrics. 10.1055/s-0037-1603977</mixed-citation>
</ref>
<ref id="CR112">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title><italic>De novo GABRG2</italic> mutations associated with epileptic encephalopathies</article-title>
<source/>Brain
          <year>2017</year>
<volume>140</volume>
<fpage>49</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="pmid">27864268</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheng</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The postsynaptic organization of synapses</article-title>
<source/>Cold Spring Harb Perspect Biol
          <year>2011</year>
<volume>3</volume>
<fpage>a005678</fpage>
<lpage>a005678</lpage>
<pub-id pub-id-type="pmid">22046028</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simon</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Strathmann</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Gautam</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Diversity of G proteins in signal transduction</article-title>
<source/>Science
          <year>1991</year>
<volume>252</volume>
<fpage>802</fpage>
<lpage>808</lpage>
<pub-id pub-id-type="pmid">1902986</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soykan</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Maritzen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Haucke</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Modes and mechanisms of synaptic vesicle recycling</article-title>
<source/>Curr Opin Neurobiol
          <year>2016</year>
<volume>39</volume>
<fpage>17</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">27016897</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<mixed-citation publication-type="other">Stoessl AJ, Mckeown MJ (2016) Movement disorders. Handb Clin Neurol 136:957–969. 10.1016/B978-0-444-53486-6.00049-1</mixed-citation>
</ref>
<ref id="CR117">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stoof</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Kebabian</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum</article-title>
<source/>Nature
          <year>1981</year>
<volume>294</volume>
<fpage>366</fpage>
<lpage>368</lpage>
<pub-id pub-id-type="pmid">6273735</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strick</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>James</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>CB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A</article-title>
<source/>Neuropharmacology
          <year>2010</year>
<volume>58</volume>
<fpage>444</fpage>
<lpage>451</lpage>
<pub-id pub-id-type="pmid">19765598</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Südhof</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Neurotransmitter release: the last millisecond in the life of a synaptic vesicle</article-title>
<source/>Neuron
          <year>2013</year>
<volume>80</volume>
<fpage>675</fpage>
<lpage>690</lpage>
<pub-id pub-id-type="pmid">24183019</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<mixed-citation publication-type="other">Talvik I, Møller RS, Vaher M et al (2015) Clinical phenotype of de novo GNAO1 mutation: case report and review of literature. Child Neurol Open 2. 10.1177/2329048X15583717</mixed-citation>
</ref>
<ref id="CR121">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Threlfell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sammut</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Menniti</surname>
<given-names>FS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation</article-title>
<source/>J Pharmacol Exp Ther
          <year>2009</year>
<volume>328</volume>
<fpage>785</fpage>
<lpage>795</lpage>
<pub-id pub-id-type="pmid">19056933</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torres</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Sweeney</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Beaulieu</surname>
<given-names>J-M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of torsinA on membrane proteins reveals a loss of function and a dominant-negative phenotype of the dystonia-associated DeltaE-torsinA mutant</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2004</year>
<volume>101</volume>
<fpage>15650</fpage>
<lpage>15655</lpage>
<pub-id pub-id-type="pmid">15505207</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tunc</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brüggemann</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Baaske</surname>
<given-names>MK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Facial twitches in ADCY5-associated disease—myokymia or myoclonus? An electromyography study</article-title>
<source/>Parkinsonism Relat Disord
          <year>2017</year>
<volume>40</volume>
<fpage>73</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="pmid">28442302</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<mixed-citation publication-type="other">Ung DC, Iacono G, Méziane H et al (2017) Ptchd1 deficiency induces excitatory synaptic and cognitive dysfunctions in mouse. Mol Psychiatry. 10.1038/mp.2017.39</mixed-citation>
</ref>
<ref id="CR125">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vemula</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Puschmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role of Gα(olf) in familial and sporadic adult-onset primary dystonia</article-title>
<source/>Hum Mol Genet
          <year>2013</year>
<volume>22</volume>
<fpage>2510</fpage>
<lpage>2519</lpage>
<pub-id pub-id-type="pmid">23449625</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<mixed-citation publication-type="other">Waak M, Mohammad SS, Coman D et al (2017) GNAO1-related movement disorder with life-threatening exacerbations: movement phenomenology and response to DBS. J Neurol Neurosurg Psychiatry. 10.1136/jnnp-2017-315653</mixed-citation>
</ref>
<ref id="CR127">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waites</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Garner</surname>
<given-names>CC</given-names>
</name>
</person-group>
<article-title>Presynaptic function in health and disease</article-title>
<source/>Trends Neurosci
          <year>2011</year>
<volume>34</volume>
<fpage>326</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="pmid">21596448</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Westenberger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Max</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brüggemann</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alternating hemiplegia of childhood as a new presentation of adenylate cyclase 5-mutation-associated disease: a report of two cases</article-title>
<source/>J Pediatr
          <year>2017</year>
<volume>181</volume>
<fpage>306</fpage>
<lpage>308.e1</lpage>
<pub-id pub-id-type="pmid">27931826</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<mixed-citation publication-type="other">Yang X, Qian P, Xu X et al (2017) GRIN2A mutations in epilepsy-aphasia spectrum disorders. Brain and Development. 10.1016/j.braindev.2017.09.007</mixed-citation>
</ref>
<ref id="CR130">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yilmaz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Turhan</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ceylaner</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Excellent response to deep brain stimulation in a young girl with GNAO1-related progressive choreoathetosis</article-title>
<source/>Childs Nerv Syst
          <year>2016</year>
<volume>32</volume>
<fpage>1567</fpage>
<lpage>1568</lpage>
<pub-id pub-id-type="pmid">27278281</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zapata</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Moretto</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hannan</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epilepsy and intellectual disability linked protein Shrm4 interaction with GABABRs shapes inhibitory neurotransmission</article-title>
<source/>Nat Commun
          <year>2017</year>
<volume>8</volume>
<fpage>14536</fpage>
<pub-id pub-id-type="pmid">28262662</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zech</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Boesch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jochim</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical exome sequencing in early-onset generalized dystonia and large-scale resequencing follow-up</article-title>
<source/>Mov Disord
          <year>2017</year>
<volume>32</volume>
<fpage>549</fpage>
<lpage>559</lpage>
<pub-id pub-id-type="pmid">27666935</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhuang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Belluscio</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hen</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>G(olf)alpha mediates dopamine D1 receptor signaling</article-title>
<source/>J Neurosci
          <year>2000</year>
<volume>20</volume>
<fpage>RC91</fpage>
<pub-id pub-id-type="pmid">10924528</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ziegan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wittstock</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Westenberger</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel GNAL mutations in two German patients with sporadic dystonia</article-title>
<source/>Mov Disord
          <year>2014</year>
<volume>29</volume>
<fpage>1833</fpage>
<lpage>1834</lpage>
<pub-id pub-id-type="pmid">25382112</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>